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Abstract 
 The pathophysiology of cerebral ischemia or acute ischemic stroke involves what is 
called neuronal "excitotoxicity", where an initial failure in intracellular energy metabolism 
causes excessive pre-synaptic glutamate release that over-stimulates ionotropic receptors, 
particularly the N-Methyl-D-aspartate (NMDA) receptor. Pharmaceutical research endeavours in 
the past decade that developed and tested therapeutics against glutamate neurotoxicity have 
exhibited dose-limiting adverse CNS effects in several large scale stroke clinical trials. Given 
their involvement in glutamatergic neurotransmission, serotoninergic compounds offer a method 
to modulate glutamate neurotoxicity without evoking unacceptable side effects.   
 A novel neuroprotective mechanism against NMDA induced excitotoxicity involves 
cross-talk between 5-hydroxytryptamine (serotonin) type 7 (5-HT7) receptor and a growth factor 
receptor called the platelet-derived growth factor β receptor (PDGFRβ). In primary hippocampal 
neurons, long-term (24 hour) activation of the 5-HT7 receptor by small molecule ligands increase 
the expression of PDGFRβ that in turn phosphorylates a downstream effector which 
differentially regulates NMDA receptor subunit expression to prevent NMDA-induced 
neurotoxicity. Direct activation of platelet-derived growth factor (PDGF)β receptors in primary 
hippocampal and cortical neurons inhibits NMDA receptor activity and attenuates NMDA 
receptor-induced toxicity. This study aimed to determine if such a neuroprotective pathway could 
be active with short-term application of a 5-HT7 receptor agonist. Western blot analysis revealed 
that 2 to 4 h activation of 5-HT7 receptors in primary hippocampal neurons increased tyrosine 
1021 phosphorylation (PLCγ binding site responsible for down regulating NR2B containing 
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NMDA receptors), as well as TrkB-FL receptor expression and phosphorylation. In addition, 
sustained increases in PLCγ1 expression and Akt activation were observed. Cell viability assays 
performed in primary hippocampal neurons showed that 2 and 4 h pre-treatment with LP 12 was 
neuroprotective against NMDA insults.  
 Similar results were observed in HT22 cells. After extensive characterization of the cell 
line, we determined that differentiated HT22 cells were susceptible to NMDA-induced 
excitotoxicity. Similar to primary neurons, HT22 cells treated with 4 h LP 12 resulted in an 
increase in tyrosine 1021, ERK1/2, PLCγ1, and Akt threonine 308 phosphorylation. MTT 
viability assays in differentiated HT-22 cells suggested that neuroprotection against NMDA can 
be observed with 4 h LP 12 pre-treatment and that a sustained rise in 5-HT7 receptor expression 
occurs during neuronal excitotoxicity.  
 These findings expand the potential role of 5-HT7 receptors as a drug target beyond 
neuropsychiatric illnesses and provide further evidence for the possibility of producing growth 
factor receptor-dependent neuroprotective effects using small-molecule ligands of G protein-
coupled receptors for neuronal excitotoxicity. 
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Chapter 1: Introduction 
This chapter begins with a brief review of all the different topics pertinent to the research 
question in this thesis. The scope of this chapter is to firstly introduce three key components of 
the research: GPCRs, RTKs, and neuronal excitotoxicity. Second, the chapter will aim to explain 
the cross-talk between the three components and create rationale for my hypothesis.  
1.1 G-protein coupled receptors and serotonin signalling 
1.1.1 G-protein coupled receptors 
 G-protein coupled receptors represent a large and diverse family of transmembrane 
receptors which all function by transducing signals from external stimuli to internal responses 
that may be either physiological or pathophysiological in nature [1]. All GPCRs have an 
extracellular amino terminus, seven membrane-spanning α-helices, and a cytosolic carboxyl 
terminus [1]. GPCRs are bound to a select variety of heterotrimeric G proteins (as their name 
suggests) in the cytosol that, upon activation, are responsible for signal transduction [1]. 
Heterotrimeric G proteins are composed of α, β, and γ subunits and upon activation the α subunit 
separates from the βγ complex and both may then interact with effector proteins [1]. Ligand 
binding to a GPCR incurs a conformational change of the receptor to an active state where the 
cytosolic guanine exchange factor domain in the GPCR results in the release of bound GDP and 
the binding of GTP to the Gα subunit, thus activating and separating the Gα subunit from the βγ 
complex [1, 2]. The intrinsic GTPase activity of the Gα subunit can terminate a transduced signal 
by hydrolyzing the bound GTP to GDP leading to the reattachment of the Gα subunit with the βγ 
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complex and subsequent reassociation with the GPCR [1, 2]. The variation in cellular and 
physiological consequences of G protein activation is largely a result of the effectors the Gα 
subunit interacts with [2], though Gβγ dimers have also been shown to modulate downstream 
effectors [3]. To date, there are 16 known Gα subunits, where the four most prominently found 
and rigorously studied are classified into four subgroups: Gαs (stimulate adenylate cyclase, AC), 
Gαi/o (inhibit AC), Gαq (activate phospholipase C, PLC) and Gα12 (activate Rho guanine-
nucleotide exchange factors, Rho GEFs ) [1,2].                      
 For the majority of GPCRs, inactivation occurs when certain threonine and serine 
residues on their C-terminal tails are phosphorylated, obstructing their physical association with 
the G protein binding domains [2]. This phosphorylation can be achieved by active protein 
kinase A (PKA) and protein kinase C (PKC) [4] and/or GPCR kinases (GRKs) [4]. Upon 
phosphorylation of GPCRs, β-arrestin molecules interact with the phosphorylation site and link 
the complex to clathrin-coated pits, leading to the internalization of GPCRs into endosomes 
[4,5]. Once internalized, the association of β-arrestins to GPCRs in endosomes determines if the 
receptor is recycled back to the membrane or undergoes lysosomal degradation [4,5].       
1.1.2 Serotonin and serotonin receptors  
 5-hydroxytryptamine (5-HT) or serotonin is a monoamine isolated in the late 1940s from 
blood serum and was first characterized mainly as a vasoconstrictor [6]. In mammals, 5-HT is 
widely distributed in blood, platelets, brain and nervous tissue, gastrointestinal enterochromaffic 
cells and smooth muscle [6]. Interestingly, 5-HT exerts its strongest actions in the brain even 
though only only 1% of the body's total 5-HT is produced in the central nervous system [7]. 
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Neurons that produce 5-HT (serotonergic neurons) are concentrated in the raphe nuclei of the 
midbrain and their fibers diffusely project to the cerebral cortex, limbic system, hypothalamus, 
hippocampal formation, and the spinal cord [8]. 5-HT has been recognized as a major CNS 
neurotransmitter that is involved in the regulation of anxiety and aggression, circadian rhythms 
and sleep, mood and perception, pain, and feeding behaviour [9]. Fourteen structurally and 
pharmacologically distinct mammalian 5-HT receptor subtypes (divided into seven main classes 
5-HT1 to 5-HT7) have been identified to date [10]. All the 5-HT receptors are of the rhodopsin 
family of GPCRs with the exception of the 5-HT3 receptor which is a ligand-gated ion channel. 
5-HT1 and 5-HT5 are Gαi-coupled receptors, 5-HT2 receptors are Gαq-coupled and finally 5-
HT4,6&7 are Gαs-coupled (stimulate AC) where the 5-HT7 receptor has also been reported to 
couple with Gα12 [10, 11]. Table 1 presents a summary of all 5-HT receptor G protein coupling, 
their major signal transduction mechanism(s), and what neurochemical event occurs (excitation 
or inhibition) at the level of a single neuron. 
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Table 1: Overview of 5-HT Receptor Subtypes As adapted from [10, 11]  
5-HT Receptor 
Family 
Gα Protein Unit 
Coupling 
Signal 
Transduction 
Mechanism  
Response at the 
single neuron level 
5-HT1 Gαi/o Inhibits AC 
(decreasing 
cellular cAMP 
levels) 
Inhibitory 
5-HT2 Gαq Activates PLCβ to 
produce IP3 and 
DAG, increasing 
cellular cAMP 
levels 
Excitatory 
5-HT3 Ligand-gated Na
+
 
and K
+
  cation 
channel 
Depolarization of 
plasma membrane 
Excitatory 
5-HT4 Gαs Stimulate AC,  Excitatory 
5-HT5 Gαi/o Inhibits AC Inhibitory 
5-HT6 Gαs Stimulate AC  Excitatory 
5-HT7 Gαs or Gα12 Stimulate AC, 
Stimulate Cdc42 
and RhoA 
(involved with 
cytoskeleton 
remodelling) 
Excitatory 
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1.2 5-HT7  receptors  
1.2.1 5-HT7 receptor properties  
 The 5-HT7 receptor is the most recently identified member of the 5-HT receptor family. 
To date 5-HT7 receptors have at least five splice variants (5-HT7a-e) in human (contains a,b, d), 
mouse (contains a,b,c) and rat (contains a,b,c,e) which differ in their C-terminal tail however 
differences in their pharmacology and/or functionality have not yet been elucidated [12-14]. 
 One established 5-HT7 receptor signalling pathway is the activation of Gαs protein which 
in vitro can activate all AC isoforms [15]; though it has been reported that the 5-HT7a isoform 
can specifically stimulate AC1 and AC8 [16]. Upon activation of AC, there is a surge in the 
levels of the intracellular second messenger molecule, cyclic adenosine monophosphate (cAMP); 
this activates the enzyme PKA which phosphorylates downstream effector proteins [16]. PKA 
can catalyze the activation of several intracellular signalling cascades which include the 
neuroprotective extracellular signal-regulated kinases (ERK) and Akt (protein kinase B) 
pathways [16].           
 5-HT7 receptors are also coupled to the Gα12 proteins that mainly activate Rho GEFs 
(among many other effectors) to ultimately initiate downstream signalling from Rho family of 
small GTPases (mainly Rho and Cdc42) [16]. Activation of Gα12 by 5-HT7 receptors appears to 
selectively activate RhoA and Cdc42 and is involved in cytoskeletal remodelling [16]. 5-HT7 
receptor-dependent activation of Cdc42 has now been shown to stimulate neurite outgrowth in 
primary cultures of cortical, hippocampal and striatal neurons in pathways that also involve the 
activation of ERK and the mammalian target of rapamycin (mTOR) [17]. A recent study by 
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Kobe et al. in 2012 showed that 5-HT7/Gα12 signalling in the hippocampus is more pronounced 
in cultured organotypic hippocampal slices from juvenile mice compared to older mice as 
measured by assessing neuronal morphology, synaptogenesis, and synaptic plasticity [18]. This 
same study further confirmed the strong developmental regulation of 5-HT7/Gα12 signalling in 
the hippocampus by reporting a progressive decrease in 5-HT7 and Gα12 protein levels in older 
neuronal cultures [20], further supporting their role in activity dependent structural and 
functional plasticity 
     5-HT7 receptors can exist as homodimers  but can also form heterodimers with the Gαi 
coupled 5-HT1A receptors in neuroblastoma N1E-115 cells and mouse hippocampal neurons [19]. 
5-HT7/5-HT1A heterodimerization increases internalization kinetics of 5-HT1A receptors (thus 
decreased activation of Gαi signalling) but spares the Gαs signalling of 5-HT7 receptors [21]. The 
physiological consequences of 5-HT7 receptor heterodimer formation has not been fully 
investigated.        
1.2.2 5-HT7 receptor functions 
 Various techniques and pharmacological compounds have been used to study 5-HT7 
receptor activation and deactivation in vitro and in vivo. The recent development of selective 5-
HT7 agonists (AS-19, LP-44, LP-12, LP-211, and E-55888), antagonists (SB-258719, SB-
269970, and SB-656104) and 5-HT7 receptor knockout mice have been used to study the 
signalling of the receptor as well as its involvement in CNS pathologies like anxiety, depression, 
schizophrenia, sleep disorder, epilepsy, and obsessive compulsive disorder (OCD) (see reviews 
[20-22]). The 5-HT7 receptor is expressed in both the CNS and the PNS. In the PNS, the 5-HT7 
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receptor is predominately found in smooth muscle cells and is involved with smooth muscle 
relaxation [23]. In the CNS, the 5-HT7 receptor is extremely abundant in the cortex, 
hypothalamus, thalamus and the hippocampus [24]. Much information has become available 
regarding the physiological role of the 5-HT7 receptor activation in the CNS being pertinent to 
regulating circadian rhythms (facilitates circadian phase shift and REM sleep) [25, 26], 
thermoregulation (induces hypothermia) [27, 28], and cognitive processes like memory 
(facilitates long and short-term memory consolidation)  [20, 29-31].     
 Given the established presence of 5-HT7 receptors in key cerebral areas coupled with the 
finding that several antipsychotics and antidepressants have high affinity for the 5-HT7 receptor, 
much attention has been dedicated to elucidating the role of 5-HT7 receptors in neuro-psychiatric 
disorders like depression, anxiety, schizophrenia and sleep disorders [32, 33]. Despite requiring 
further validation, pre-clinical studies completed to date support using 5-HT7 receptor 
antagonists to ameliorate effects of schizophrenia, anxiety and especially depression. For 
depression, the pharmacological inhibition of the 5-HT7 receptor synergistically enhances the 
anti-depressive effects of clinically used antidepressants [34, 35]. New individual therapies for 
neuropsychiatric disorders targeting the blockade of 5-HT7 receptors in combination with using 
current antidepressants are currently under investigation [22]. 5-HT7 receptor blockade is one of 
the key pharmacological features of vortioxetine, an atypical antidepressant that was approved 
by the U.S. FDA for the treatment of major depressive disorder in 2013 [36]. 
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1.3 Neurotrophic factors and receptor tyrosine kinases (RTKs) 
 In general, neurotrophic factors or growth factors bind to cell surface receptors or 
receptor tyrosine kinases (RTKs) and initiate signaling cascades like phosphatidylinositol 3-
kinase (PI3K) /Akt (cell survival), MAP Kinase (neurite outgrowth and neuronal differentiation), 
and PLC-γ (activity dependent plasticity) that result in the proliferation and growth of different 
cell types [37, 38]. Strictly speaking, the two major families of neurotrophic factors are the 
neurotrophin family and the glial cell line-derived neurotrophic factor (GDNF) family [38]. The 
neurotrophins comprise of nerve growth factor (NGF), neurotrophin-3, neurotrophin 4 (NT-3, 
NT-4) that bind to the tropomyosin related kinase (Trk) family of receptor tyrosine kinases A, B 
and C that can all activate the previously mentioned signalling cascades [38]. These particular 
neurotrophins can also bind to the p75 neurotrophin receptor that can initiate cell death pathways 
[44]. In contrast, the glial cell line-derived neurotrophic factors (GDNF) comprise of GDNF, 
neurturin, and persephin which all exhibit distant homology with the transforming growth factor 
beta (TGFβ) family of ligands [38]. They signal through a receptor complex composed of the Ret 
tyrosine kinase and glycosyl-phosphatidyl inositol-anchored coreceptor (GFRα family: GFRα1, 
α2, α3, and α4) making them potent axon-promoting growth factors in vivo for developing 
sympathetic and parasympathetic neurons [38].      
 Any growth factor that promotes neuronal survival and growth could be described as a 
neurotrophic factor. Binding of the neurotrophic factor causes receptors to dimerize, resulting in 
the intracellular kinase catalytic domains coming into close proximity and becoming 
phosphorylated [39]. The phosphorylation of the kinase domain activation site leads to the trans-
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autophosphorylation of several other tyrosine kinase residues in the intracellular tail, allowing 
the phosphorylated tyrosine residues to become docking sites for signaling enzymes and adaptor 
proteins, which predominately initiate pro-survival proliferative signaling cascades mentioned 
earlier [39]. Based on this classic definition, factors known for their hormone functions and 
peripheral effects like insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF), 
platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and 
fibroblast growth factor (FGF) should also be considered in the scheme of neurotophic factors 
which act on RTKs. Two important growth factors are relevant to this proposed research: 
platelet-derived growth factor (PDGF) and brain-derived neurotrophic factor (BDNF) which bind 
to RTKs called PDGF receptors (PDGFRs) and tropomyosin-receptor kinase (Trk) neurotrophic 
receptors, respectively. 
1.3.1 Platelet derived growth factor receptors 
 PDGFs are powerful mitogens that act on a range of cell types which include CNS 
neurons, smooth muscle, fibroblasts and vascular endothelial cells [39]. PDGFs have been 
divided into four subtypes (A to D) with PDGF-A and PDGF-B being the most extensively 
researched [37]. PDGFs are typically found as homodimers . PDGF-BB can bind to PDGFβ 
receptors (PDGFRβ) whereas the α receptor binds all but PDGF-DD [37]. The work presented in 
this thesis is pertinent to the PDGFβ receptors given their exclusive expression in pyramidal 
neurons of the hippocampus [40] (it should be noted that PDGFα receptors do express in the 
hippocampus albeit showing higher expression in non-neuronal cells [37]). Upon PDGFβ 
receptor activation, the trans-autophosphorylation of several tyrosine residues on the cytoplasmic 
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tails serve as docking sites for some key signalling enzymes and adaptors that generally initiate 
proliferative signalling (see Table 2). PDGFβ receptors are found in caveolae and ligand 
activation can also quickly internalize the receptor in a clathrin-dependent manner [39, 41].  
 The physiological role of the PDGFβ receptor is critical in mammalian development and 
normal function. PDGFβ receptor knockout mice display severe perinatal defects that include 
kidney failure, cardiovascular defects, limited ability to repair wounds, and pulmonary 
abnormalities [42]. In the CNS, PDGF signalling is required for proliferation of oligodendrocytes 
and the production of myelin [37]. Conversely, excessive activity of the PDGFβ receptor activity 
is implicated in atherosclerosis and fibrosis as well as tumor formation and progression [43].            
1.3.2 Neurotrophins and TrkB receptors 
 Neurotrophin binding to Trk receptors predominantly promotes survival and maintenance 
of neurons especially during pathophysiological CNS events that cause neuron damage [43].  
Each Trk receptor subtype has different affinities for different neurotrophins: TrkB receptors can 
bind BDNF, NT-3, or NT-4 [44], while TrkA receptors bind NGF, and TrkC receptors bind NT-
3 [43]. Similar to PDGFRβ, the TrkB receptor dimerizes upon ligand binding leading to kinase 
domain activation and transautophosphorylation of its intracellular tyrosine residues that act as 
docking sites for signalling enzymes and adapter proteins (see Table 3).      
 Three alternatively spliced isoforms of the TrkB receptor in humans are responsible for 
much of the neurotrophin signalling. The first isoform is the full length (TrkB-FL) receptor that 
dimerizes upon ligand binding and is responsible for intracellular signalling. The other two 
isoforms are the truncated TrkB-T1 and TrkB-Shc which have a ligand binding and 
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transmembrane domain but lack the intracellular kinase domain. Despite being truncated, TrkB-
T1 and TrkB-Shc are able to modulate the activity of the full-length TrkB receptor by forming 
heterodimers with the full length receptor and also by competing for BDNF [38, 45]. Synaptic 
activity that causes a strong post-synaptic calcium ion influx (such as in long-term potentiation) 
can cause clathrin-dependent internalization of BDNF bound TrkB receptors [46]. Additionally, 
and much like the PDGFβ receptor, ligand binding also causes clathrin-dependent internalization 
of TrkB receptors but internalization does not mean deactivation given internalized TrkB 
receptors still participate in downstream signalling [47].   
Table 2. PDGFβ receptor signalling as adapted from [39] 
Signaling 
Molecule 
RTK 
phosphorylation site 
Pathways activated and signaling consequences 
PDGFβ receptor 
kinase domain 
activation site 
Y857 Activation of receptor kinase activity and trans-
autophosphorylation of other tyrosine residues on the 
cytoplasmic tail. 
 
PLCγ1 Y1021 and Y1009 Ca2+signaling, mitagenicity and in some cell migration, 
inhibition of NMDA and GABAA receptors 
PI3K Y740 and Y751 Akt/PKB pathway 
Grb2 Y716 and Y775 Sos/Ras/MAPK pathway 
Grb7 Y716 and Y775 Migration of neuronal cells in embryo 
Stat5 Y579, Y581 and Y775 Activation and translocation to nucleus leads to gene 
expression related to proliferation, differentiation and 
apoptosis 
Shc Y579, Y740,  Y751, 
Y771 
Grb2/Ras/MAPK pathway 
Nck Y751 Proliferation 
SHP-2 Y1009 and Y763 Negatively: dephosphorylates autophosphorylation site 
Tyr740/Tyr751/Tyr771. Positively: Grb2/Ras/MAPK 
pathway, Src/MAPK pathway  
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Table 3. TrkB receptor signaling as adapted from [48] 
Signaling Molecule RTK 
phosphorylation 
site 
Pathways activated and signaling consequences 
Shc which then binds 
Grb2/SOS 
 
 
Y515 Activation of the MAPK signalling cascade promoting 
neuronal differentiation and growth through extracellular 
signal-regulated kinase (ERK). 
Activation of the phosphatidylinositol 3-kinase (PI3K) 
cascade promoting survival and growth of neurons 
through Ras or GRB-associated binder 1 (GAB1). 
PLCγ1 Y816 Generation of inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) 
(IP3) and diacylglycerol(DAG).  
 
DAG stimulates protein kinase C (PKC) isoforms and IP3 
promotes the release of Ca2+ from internal 
stores and subsequent activation of Ca2+/calmodulin 
(Ca2+/CaM)-dependent protein kinases (CaMKII, 
CaMKK and CaMKIV). 
 
1.4 GPCR regulation of RTKs   
 Apart from the ligand-dependent activation of RTKs described previously, several studies 
to date have shown that dimerization and transautophosphorylation of RTKs can occur in a 
ligand-independent manner. The most common type of ligand-independent RTK activation is 
GPCR-induced transactivation. Examples of GPCR mediated activation of RTKs outside the 
nervous system include angiotensin II (agonist of angiotensin receptor II) activating PDGFβ 
receptors in vascular smooth muscle cells [49], thrombin (agonist of protease-activated receptor) 
activating insulin growth factor-I receptor (IGFR-1) in aortic smooth muscle cells [50] and 
endothelin-1 or lysophosphatidic acid (LPA) or thrombin induced activation of epidermal growth 
factor receptor (EGFR) in rat-1 fibroblasts [51] (see review [52] among many others).  
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 In the nervous system, agonists of GPCRs can also activate RTKs in a transient fashion 
i.e., short exposure of GPCR to agonist bringing about a short-lived activation of a RTK. Some 
prominent examples include dopamine 4 (D4) and the dopamine 2 (D2) receptor stimulation 
activating PDGFRs in Chinese hamster ovary (CHO-K1) cells [53]. Activation of 5-HT1A 
receptor with 5-HT transactivates PDGFRβ and TrkB in human SH-SY5Y neuroblastoma cell 
line as well as mouse primary cortical neurons [54, 55]. Similarly, D2-class dopamine receptor 
transactivation of PDGF receptors in ex vivo hippocampal neurons [56].  
1.4.1 5-HT7 regulation of PDGFβ receptor 
 Research continues to clearly elucidate the physiological relevance and exact 
mechanisms of ligand-independent transactivation of RTKs [55]. A related series of studies 
described in Beazely lab (University of Waterloo School of Pharmacy) suggest that long-term (2-
24 h) exposure of 5-HT7 receptors to 5-HT, 5-carboxamidotryptamine (5-CT) or 5-HT7 receptor 
selective agonist (LP 12) increase PDGFRβ expression and basal phosphorylation at the PLCγ 
binding site in primary mouse hippocampal, and cortical neurons as well as the SH-SY5Y 
neuroblastoma cell line [57]. Figure 1 (adopted from [62]) shows that 24 hour treatment of 
primary hippocampal neurons with 300 nM LP 12 increased PDGFRβ receptor expression; an 
increase that was blocked by SB 269970 (an inverse 5-HT7 receptor agonist) and SB 258719 
(neutral 5-HT7 receptor antagonist) (see Figure 1A and B). Similar increases in PDGFRβ 
expression were seen after 24 h treatment of primary cortical neurons and SH-SY5Y 
neuroblastoma cells by 300 nM LP 12 (Figure 1C and D). Accordingly, Vasefi et al., (2012) 
investigated if LP 12 was able to increase PDGFRβ expression as well as phosphorylation at the 
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PLCγ binding site at shorter time frames (4 h to 18 h). In primary mouse hippocampal neurons, a 
significant bimodal effect on PDGFRβ expression at 8 h and 24 h LP 12 treatment was shown, 
though the non-significant increase at 4 h should not be ignored (Figure 2A). In primary mouse 
cortical neurons, an LP 12 time-course only shows a significant increase on PDGFRβ expression 
at 24 hours (Figure 2B). Interestingly, 4 h and 24 h LP 12 administration showed significant 
increases in PDGFRβ expression in SH-SY5Y cells (Figures 2B and 2C are unpublished data 
sets that belong to first author of [62]).       
 In summary, Vasefi et al (2012) has shown that 24 hour treatment with a selective 5-HT7 
receptor agonist like LP 12 is sufficient to significantly increase the expression of PDGFRβ 
expression and phosphorylation at the PLCγ binding site where the natural ligand PDGF-BB was 
not involved. The LP 12 administration time course for 4 h to 8 h 5-HT7 exposure to agonist was 
inconclusive where additional experiments that test the same mechanism between 1-8 h agonist 
exposure form an important part of the current investigation. 
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Figure 1. 24 h LP 12 treatment increases PDGFβ receptor expression in primary 
hippocampal and cortical neurons as well as in SH-SY5Y neuroblastoma cell line.      
A) Hippocampal neurons were incubated for 24 h with LP 12 (300 nM) with or without or 1 μM SB 
269970, a 5-HT7 receptor inverse agonist. LP 12 increased PDGFβ receptor expression and this was 
reduced by co-incubation with SB 269970 (n = 7). B) LP 12 (300 nM) was added to hippocampal cultures 
for 24 h in the presence or absence of the neutral 5-HT7 receptor antagonist SB 258719 (1 μM, n = 5). C) 
LP 12 (300 nM) was added to cortical cultures for 24 h in the presence or absence of the neutral 5-HT7 
receptor antagonist SB 258719 (1 μM, n = 4).  D) LP 12 (300 nM) was added to SHSY5Y cells for 24 h 
in the presence or absence of the neutral 5-HT7 receptor antagonist SB 258719 (1 μM, n= 5). For A* p 
<0.01, ANOVA analysis with Dunnett’s post-test. For B-D * p < 0.05, ANOVA analysis with Dunnett’s 
post-test. The fold-change in PDGFRβ expression was determined by quantification of Western blots.  
Figure As adapted from [57]. 
Hippocampal neurons Hippocampal neurons 
Cortical neurons SH-SY5Y Cells 
C D 
B A 
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Figure 2. LP 12 time course for PDGFβ receptor expression in hippocampal and cortical 
neurons and SH-SY5Y neuroblastoma cell line.                           
A) Hippocampal cultures were incubated with 300 nM LP 12 for 4-24 h, n=3. (* p < 0.05, ANOVA 
analysis with Dunnett’s post-test) The fold-change in PDGFβ receptor expression was determined by 
quantification of Western blots, n = 3 (*p < 0.05, ANOVA with Dunnett’s post-test) [57] The cortical 
cultures (B) and SH-SY5Y cells (C) were incubated with 300 nM LP12 for 0–24h. The fold-change in 
PDGFβ receptor expression was determined by quantification of Western blots, n = 3 (*p < 0.05, 
ANOVA with Dunnett’s post-test) (Data not published but belongs to first author of [62].  
 
Cortical neurons 
SH-SY5Y cells 
Hippocampal neurons 
A 
B 
C 
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1.4.2 5-HT7 regulation of TrkB receptors 
 Multiple GPCRs have the ability to transactivate TrkB receptors and exert trophic effects 
in neurons. Adenosine A2A receptors [58, 59], 5-HT1a receptors [55], dopamine 1 (D1) 
receptors, human secretin receptor (SCTR) [60], and CB1 cannabinoid receptor [61] have all 
been shown to modulate TrkB receptor expression and signalling in neuronal systems. Evidence 
of 5-HT7 receptors modulating TrkB activity was scarce until a physiological role for 5-HT7 
receptors in a form of respiratory motor plasticity, termed phrenic motor facilitation (pMF), was 
discovered [62, 63]. Phrenic motor facilitation is a general term used to describe a long lasting 
firing of phrenic motor neurons elicited by acute exposure to intermittent hypoxia [68]. 5-HT7 
receptor agonists induce pMF via Epac (exchange protein directly activated by cAMP)-Akt-
mTORC1 signalling, a mechanism where new synthesis of an immature TrkB isoform is 
required, but not new BDNF synthesis [64]. Work done by this group suggests that for 5-HT7 
receptor agonist dependent pMF to occur, i) ERK and Akt signalling must be active but no TrkB 
expression is neccessary in the early phase of pMF, and ii) in the late phase of pMF TrkB 
transactivation along with PI3K activation is necessary [69].          
 Interestingly, a recent study from Beazely lab has reported that 5-HT7 receptor selective 
agonist, LP 12, increases the expression of TrkB and phosphorylation of its tyrosine residue 
Y816 (that binds PLCγ) in the SH-SY5Y and RGC-5 cell lines and to some extent in primary 
mouse cortical cultures [65]. Using a similar experimental set up (same agonist and antagonist 
concentration as well as treatment time schemes) as Vasefi, et al. (2012) where the focus was 5-
HT7-PDGFβ receptor signalling, this paper reported 5-HT7 dependent significant increases in 
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TrkB-FL expression and phosphorylation in SH-SY5Y and RGC-5 cells with 24 h agonist 
exposure [71]. Conversely, with 2 h agonist exposure similar increases in TrkB-FL expression 
were observed in SH-SY5Y and RGC-5 cells and phosphorylation at Y816 was only 
significantly increased in RGC-5 cells [71]. The transactivation effects of LP 12 treatment in the 
short-term (15 min to 4 h) was also assessed in this study where there was a transient rise in 
Y816 phosphorylation at 15 min in SH-SY5Y cells but a more sustained rise between one and 
four hours in RGC-5 cells [71]. Although preliminary, these results suggested that, in addition to 
PDGFβ receptors, 5-HT7 receptors may also positively regulate TrkB receptors. 
1.5 N-Methyl-D-aspartate (NMDA) glutamate receptors, RTKs, and GPCRs   
 Growth factors and neurotrophin receptors like PDGFRβ and TrkB, respectively, as well 
as certain GPCRs have long been known to modulate the activity of an excitatory ion channel in 
the CNS called the N-Methyl-D-aspartate (NMDA) receptor that has implications in almost all 
the prominent CNS neurodegenerative and neurological disorders. This section will elaborate on 
the cross-talk between the three systems in the context of NMDA receptor mediated neuronal 
excitotoxicity.   
1.5.1 Glutamatergic neurotransmission and NMDA receptors 
 The ionotropic glutamate channels mediate most of the fast synaptic transmission in the 
CNS [66]. There are three main subtypes of the glutamate receptor (each named after a chemical 
agonist): i) NMDA (N-methyl-D-aspartic acid), ii) AMPA (α-amino-3-hydroxy-5-
methylisoxazole-4-propionate) and iii) KA (Kainic Acid) [72]. The neurotransmitter glutamate 
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activates all three receptor subtypes, however, AMPA acts only at AMPA receptor, NMDA acts 
only at NMDA receptor and so on. NMDA and AMPA receptors each have distinct 
physiological properties and often coexist at the same synapse, as a result most glutamate 
mediated excitatory post-synaptic potentials (EPSPs) have components contributed by both 
receptors [72]. The AMPA-gated channels are permeable to both Na
+
 and K
+
 and most are not 
permeable to Ca
2+ 
[72]. The net effect of AMPA-gated channel activation at normal negative 
membrane potential is the influx of Na
+
 into cell causing a rapid and large depolarization of the 
post synaptic membrane which renders the NMDA channel active by removing the constitutive 
channel blocker, Mg
2+
, from the NMDA channel ion pore [72]. Consequently, the NMDA-gated 
channels cause excitation of a cell by admitting Na
+
 but differ from AMPA receptors in two 
ways: i) NMDA receptors are permeable to Ca
2+
, and ii) the inward ionic current through them is 
voltage dependent i.e., they will only fire upon membrane depolarization and removal of the 
Mg
2+
 block [72]. Glutamate activation of AMPA receptors and consequently of NMDA 
receptors, NMDA receptor dependent calcium influx, and the trafficking of AMPA receptors in 
the CA1 region of the hippocampus form the basis of synaptic plasticity [67, 68].     
 The NMDA receptors are a heterogeneous group of ion channels that exist as cation-
selective tetramers formed by homo- and hetero-oligomeric assembly of subunits with common 
structural features that include [66]:  
 an extracellular amino (N')-terminal,  
 three transmembrane domains (M1, M3 and M4) ,  
 a channel lining re-entrant 'p-loop' (M2) and  
 an intracellular carboxy (C')-terminal.  
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 The two extracellular segments S1 and S2 (a binding pocket created by two regions 
present in the N-terminus and the extracellular loop between M3 and M4) have been shown to 
comprise the ligand binding domain on the NR2 subunits which is responsible for binding both 
the neurotransmitter and competitive agonists/antagonists of the receptors [72]. The re-entrant 
M2 loop comprises of the channel pore and determines calcium permeability of the channel and 
magnesium blockade of the ion pore [72]. 
 NMDA receptors are comprised of three major subfamilies of subunits: the ubiquitously 
expressed NR1 subunit, four distinct NR2 sub-units (A–D), and two NR3 members (A and B) 
[72]. Glutamate/glycine responsive NMDA receptors require both, dimers of NR1 and dimers of 
NR2 subunits in order to be functional [72]. Generally, NR2A and NR2B containing NMDA 
receptors (paired with NR1) are the predominant receptors expressed in the forebrain and 
hippocampus, NR2C is expressed largely in cerebellar granule cells, and NR2D expression is 
limited to diencephalon and midbrain for early development [72]. NMDA receptors that complex 
with NR3 subunits generally are not functional [72]. The current consensus in NMDA receptor 
neurobiology is that much of the NR2A containing NMDA receptors are predominantly 
expressed at synaptic sites whereas NR2B containing NMDA receptors are located at 
extrasynaptic sites in the adult CNS [72, 73, 74].  
1.5.2 NMDA receptors and neuronal excitotoxicity 
 Large concentrations of glutamate present for excessive amounts of time can “excite 
neurons to death”. The neurodestructive potential of glutamate (coined excitotoxicity) was first 
  21 
established by the demonstration that an overdose of systemic glutamate destroys hypothalamic 
nuclei in immature monkeys and rodents [69]. Follow-up research demonstrated that high 
concentrations of glutamate [100–500 mM] induced cell death in vitro and that similar 
extracellular concentrations are present in the rodent brain and spinal cord during ischemia [70, 
71]. Subsequently, AMPA and NMDA receptor-mediated, glutamate-induced cell death in vitro 
and in vivo models of ischemia was described [72]. The excessive release of the excitatory amino 
acid glutamate in excitotoxicity is dependent on the type of insult (acute or chronic) to the CNS 
which varies between diseases. For instance, in acute ischemic stroke and brain injury severe 
ATP depletion and energy impairment occurs earlier on in the ischemic cascade which 
excessively activates NMDARs causing excessive influx of Ca
2+
 and Na
+
 with the efflux of K
+
 
(intracellular ionic imbalance), overloading mitochondria resulting in free radical production and 
activation of other downstream proteases, lipases and nucleases that lead to predominantly a 
necrotic form of neuronal injury and gradual apoptotic cell death [73].    
 Unlike acute forms of excitotoxicity seen in ischemic stroke or traumatic brain injury, a 
slower, more subtle form of excitotoxicity is implicated in progressive neurodegenerative 
disorders like Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, 
HIV associated dementia, glaucoma, and amyotrophic lateral sclerosis [74]. In these disease 
modalities a more chronic exposure to elevated glutamate concentrations slowly and 
cumulatively triggers apoptotic-like cell death in neurons that is mediated by extra-synaptic 
NMDARs (NR2B-containing) [75-77] where the synaptic (NR2A containing) NMDARs are 
thought to be pro-survival [78, 79] (See Figure 3). Conversely, in acute ischemic stroke the 
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excessive release of glutamate in synaptic and extrasynaptic sites causes global populations of 
NMDA receptors to be activated causing pro-apoptotic neuronal calcium ion concentrations to 
rise [85]. The mechanisms by which NR2B subunits initiate cell death and NR2A subunits 
preserve synaptic activity are largely due to differences in the signalling proteins directly bound 
or indirectly coupled to the long C-terminal domains of these subunits [85]. While NR2A 
subunits bind to or associate with signalling proteins that activate Akt, ERK, and CREB, NR2B 
subunits in extrasynaptic sites serve as a hub for a plethora of death signalling proteins [85] that 
have been summarized in Table 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As adapted from [84, 85]. 
Figure 3. NMDAR subunit dependent mechanisms of neuronal excitotoxicity 
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Table 4. Extrasynaptic NMDA receptors and associations with death signalling proteins. 
Information as adapted from reviews [80, 81]. 
Signaling molecules associated with NR2B 
containing NMDA receptors  
General mechanisms of action in excitotoxicity 
DAPK1 (death-associated protein kinase 1) Excessive Ca
2+ 
influx
  
in excitotoxicity causes 
calcineurin to de-phosphorylate DAPK1(inactive 
when phosphorylated) which augments NR2B 
subunits to futher mediate excitotoxicity and also 
binds to ERK to suppress any survival signalling 
nNOS (neuronal nitric oxide synthase) Indirectly bound toNR2B subunits by PSD-95 
protein where a NR2B-PSD95-nNOS death 
complex is formed which produces severe 
oxidative stress via production oxygen and nitrogen 
oxide free  radicals. 
Calpain A death promoting protease that mediates protein 
cleavage specifically of substrates that bind to cdk5 
(cyclin dependent kinase): p35 and p25. The 
truncation of neuroprotective p35 to p25 redirects 
cdk5 towards neuronal death.  
STEP (striatal-enriched protein tyrosine 
phosphatase) 
Calpain mediated truncation of p38 bound STEP 
(survival signalling through MAPK) to inactive 
STEP33 contributes to neuronal death 
PTEN (phosphatase and tensin homolog deleted on 
chromosome ten) 
A death promoting protein phosphatase bound to 
NR1 subunit of extrasynaptic NR2B containing 
NMDA receptors. De-phosphorylates plasma 
membrane protein PIP3 into PIP2 which prevents 
Akt translocation into nucleus and survival 
signallling. 
1.5.3 Current Treatments for NMDA receptor mediated neuronal excitotoxicity  
 The clinical failure and side effects of competitive antagonists and several NMDA 
receptor ion-channel blockers against neuronal excitotoxicity, in conditions like ischemic stroke, 
are well documented in current literature that has synthesized two decades of failed clinical 
attempts [82]. The primary reasoning behind the failure of these compounds pertains to their 
mode of action: competitive agonists compete with glutamate in all areas of the brain which also 
blocks normal brain function and ion-channel blockers to date have possessed an undesirably 
high affinity for the Mg
2+
 site that also blocks normal neuronal function [74, 82].  
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 Given the mechanisms of excitotoxic damage, a clinically acceptable anti-excitotoxic 
drug needs to have a two-fold mechanism of action in which i) excessive activation of NMDARs 
must be blocked and ii) normal functioning of NMDARs must be kept intact to avoid adverse 
side effects. To date, only one compound, memantine, is being tested for several 
neurodegenerative disorders given its approval for mild to moderate Alzheimer's disease (a 
putative treatment for chronic neuronal excitotoxicity) [83]. Memantine is currently undergoing 
clinical trials for glaucoma, neuropathic pain, substance abuse, multiple sclerosis an epilepsy and 
acute ischemic stroke  [clinicaltrials.gov]. Memantine exerts its effects by binding preferentially 
at or near the Mg
2+
 binding site within the ion pore [84]; this finding coupled with strong 
electrophysiological kinetic data suggests that memantine preferentially blocks NMDAR 
activation if the probability of the ion channel to be in open configuration is much higher, i.e., 
under excitotoxic conditions. Memantine likely only acts under pathological conditions in low 
doses without substantially affecting normal neuronal synaptic function though high doses of 
memantine are contraindicated for patients at risk of acute ischemic stroke as it is able to block 
global populations of NMDA receptors [85].    
1.5.4 RTKs and neuronal excitotoxicity 
 In the last decade several pre-clinical studies have put forth consistent findings of growth 
factor receptors and their agonists (like PDGFβ receptor/PDGF-BB) and neurotrophin receptors 
and their agonists (like TrkB/BDNF) exerting neuroprotective effects against neuronal 
excitotoxicity in different model systems. With regards to PDGF and PDGF receptors, a few 
studies initially reported that there was an increased expression of PDGF receptor ligands, 
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especially PDGF-B chain isoform mRNA transcripts, as well as PDGF receptors in neurons and 
support cells surrounding the lesioned area of the CNS in animal models of stroke [86, 87]. 
Subsequent to these findings it was shown that administration of PDGF-BB inhibits NMDA-
evoked currents and excitatory postsynaptic potentials that are mediated by the NR2B-containing 
NMDA receptors in primary CA1 hippocampal neurons [88, 89], one of the proposed 
mechanisms in studies that showed neuroprotection of hippocampal neurons from glutamate or 
NMDA-induced excitotoxicity [90, 91]. Apart from the direct inhibition of the NR2B subunit 
expression in NMDA-excitotoxicity, Beazely et al., (2009) also showed that PDGF-BB 
administration leads to phosphorylation of downstream pro-survival transcription factor ERK 
and also prevented the NR2B receptor inhibition of ERK and CREB phosphorylation.      
 There is strong evidence for cross-talk between PDGFRβ and the NMDA receptor that is 
able to explain the pre-clinical neuroprotection achieved thus far against glutamate or NMDA 
induced excitotoxicity in vitro. On the other hand, the neuroprotective mechanisms by which 
BDNF brings about neuroprotection against acute ischemia in vivo (see studies [92, 93]) did not 
suggest TrkB modulation of NMDA receptors as a mechanism of action. In other studies, 7,8-
dihydroxyflavone (7,8-DHF), a small-molecule flavone derivative that binds with high affinity 
and specificity to TrkB, has been shown to exert neuroprotection against glutamate-induced 
toxicity in the hippocampal HT-22 cell line [94] and in an in vivo model of cerebral ischemia and 
reperfusion (I/R) injury in rats [95]. The proposed mechanism of neuroprotection in studies 
outlined thus far are heavily in favour of the antioxidant properties of BDNF (or 7,8-DHF) that is 
able to increase cellular glutathione levels and reduces ROS production as well as the activation 
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of the signaling pathways MAPK, PI3K and PLCγ. In normal physiology, post synaptic 
activation of TrkB receptors via BDNF causes them to interact with NMDA receptors via a 
protein tyrosine kinase called Fyn which increases the open probability of the NMDA ion 
channel (see review [48]). BDNF levels are significantly increased above baseline values during 
the first 4 h and up to 24 h after ischemic insult in vivo [96, 97] thus, it remains to be seen if the 
neuroprotective effects of BDNF or TrkB activation could also be a result of direct inhibition of 
specific NMDA receptor subunits as is the case with PDGF-BB.           
1.5.5 GPCRs and neuronal excitotoxicity  
 There is ample evidence of GPCRs regulating NMDA receptor activity in normal brain 
physiology. GPCRs involved in dopaminergic, GABA-ergic, cannabinergic, cholinergic 
neurotransmission are responsible for NMDA receptor regulation in a sub-type specific manner 
[98]. In fact, all serotonin receptors take some part in regulating NMDA receptor activity. 
Examples include 5-HT2B receptors being involved in enhanced pre-synaptic firing to depolarize 
NMDA receptors [99] and 5-HT1A receptors being involved in hyperpolarization of post-synaptic 
terminals which inhibits NMDA currents [100]. No attempt to date has resulted in a 
comprehensive list of GPCRs that can act as strategic targets for neuronal excitotoxicity. For 
instance, the inhibitory property of 5-HT1A receptors against NMDA receptors was grounds for 
clinical assessment, albeit unsuccessful, in an acute ischemic stroke trial [101]. The role of 5-
HT7 receptors in neuronal excitotoxicity is merely speculative at this stage given their ability to 
enhance hippocampal NMDA currents in acute treatments (5-10 min) [102] but have indirect 
(RTK dependent) inhibitory effects on NMDA receptors with longer activation [103].      
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1.6 Targeting 5-HT7 receptors and RTKs for neuronal excitotoxicity 
 Based on the findings that 5-HT7 receptor-selective and non-selective agonists can 
increase expression and phosphorylation of PDGFRβ, and that PDGFRβ  are able to selectively 
modulate extrasynaptic NR2B subunits during excitotoxicity, Vasefi et al., (2013) showed that 
24 hour pre-administration of 5-HT7 receptor agonist, LP 12, is neuroprotective against NMDA-
induced excitotoxicity in primary hippocampal neurons. Vasefi et al., utilized the kinase 
inhibitors STI-571 and AG1296 to confirm that the neuroprotection was indeed dependent on 
kinase activity of the PDGFβ receptor as both the inhibitors prevented LP-12 induced 
neuroprotection and blocked the reduced expression of the NR1 and NR2B subunit. The 
involvement of the 5-HT7 receptor in this pathway was confirmed by the observations that two 5-
HT7 receptor antagonists (SB 258719 and inverse agonist SB 269970) blocked all of LP 12's 
effects [103]. See Figure 4 for a schematic of the proposed mechanism by which long-term 5-
HT7 agonists can modulate NMDA receptor activity. 
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Figure as adapted from [103].         
 Given that 5-HT7 neuroprotection is dependent on RTKs such as PDGFRβ and 
potentially even TrkB [65], this mechanism opens up an opportunity to use selective small 
molecule agonists for 5-HT7 receptors that can cross the blood brain barrier (BBB) to enhance 
endogenous growth factor signals before, during or shortly excitotoxic insults. The clinical use of 
growth factors for neurological diseases is limited by major adverse effects, short in vivo half-
lives, poor delivery and the inability of these large proteinaceous ligands to penetrate the BBB 
[104, 105]. Vasefi et al., (2013) have put forth a mechanism that is neuroprotective against 
excitotoxicity after 24 h pre-incubation with LP 12, however, this time frame is far too long to 
significantly rescue damaged neurons in the acute phase of neuronal excitotoxicity. The 
objectives presented in this thesis are ultimately to study if short-term (15 min to 4 h) activation 
of 5-HT7 receptors is able to similarly protect neurons against neuronal excitotoxicity.  
Figure 4. Long-term activation of 5-HT7 receptors is neuroprotective against NMDA excitotoxicity 
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Chapter 2: Objectives and Hypothesis 
The objectives of this project are: 
1. Characterize the short-term (15 min to 4 h) effects of LP 12 on PDGFβ and TrkB receptor 
expression and signalling activity in neuronal cell lines and primary neuronal cells   
2. Determine if short-term pre-treatment with LP 12 is neuroprotective against 
excitotoxicity and whether if the neuroprotection is PDGFβ and/or TrkB receptor 
dependent   
These objectives have been made to fulfill the hypothesis that: 
Short-term (1-4 h) 5-HT7 agonist treatment of primary neurons and differentiated HT-22 
cells will be neuroprotective against NMDA-induced excitotoxicity via increases in 
PDGFRβ and TrkB expression and basal signaling activity (phosphorylation) 
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Chapter 3: Materials and Methods 
3.1 Reagents and Antibodies 
 LP 12 (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1- 
piperazinehexanamide hydrochloride), NMDA (N-methyl-D-aspartate), L-glutamic acid, PDGF-
BB, glycine, and other chemical reagents were purchased from Sigma (St. Louis, MO, USA). 
AG1296 (6,7-Dimethoxy-2-phenylquinoxaline). Imatinib mesylate (STI-571) (4-[(4-methyl-1-
piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-
methanesulfonate-benzamide) was purchased from Novartis (Basel, Switzerland). The 5-HT7 
receptor antagonists SB 258719 ((R)-3,N-Dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-
yl)propyl]benzene sulfonamide) and SB 269970 ((2R)-1-[(3-Hydroxyphenyl)sulfonyl]-2-[2-(4-
methyl-1-piperidinyl)ethyl] pyrrolidine hydrochloride) and the NMDA receptor antagonist MK-
801 (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate 
were obtained from Tocris (Ellisville, MO, USA). The antibodies used, their molecular weight, 
isoform and and manufacturer are listed in Table 5 below: 
Table 5. Antibodies 
Antibody Isotype Molecular 
weight (kDa) 
Manufacturer 
PDGFβ receptor Rabbit 190 Santa Cruz 
PDGFβ receptor phospho-tyrosine 
1021 
Rabbit 190 Santa Cruz 
TrkB-FL, TrkB-Shc, TrkB-T1 Rabbit 145, 105, 95 Santa Cruz 
phospho-TrkB Y816 Rabbit 145 Abcam 
NR1 Rabbit 120 Cell Signaling 
NR2A Rabbit 180 Cell Signaling 
NR2B Rabbit 190 Cell Signaling 
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Table 5 continued    
β-Actin Mouse 45 Santa Cruz 
Cytochrome C Rabbit 14 Cell Signaling 
PLCγ1 Rabbit 150 Cell Signaling 
p-ERK1/2 Rabbit 42, 44 Cell Signaling 
ERK1/2 Rabbit 42, 44 Cell Signaling 
5-HT7  Rabbit 50 Rockland and Fisher 
p-Akt Threonine 308 Rabbit 60 Cell Signaling 
Akt  Rabbit 60 Cell Signaling 
Anti-mouse horseradish peroxidase 
(HRP) enzyme-conjugated IgG 
Goat Secondary Fisher 
Anti-rabbit horseradish peroxidase 
(HRP) enzyme-conjugated IgG 
Goat Secondary Fisher 
Anti-rabbit Dylight 488 Goat Fluorescently 
labeled 
secondary 
Fisher 
3.2 Cell Culture 
3.2.1 SH-SY5Y neuroblastoma cell line 
 Neuroblastoma cells were cultured in DMEM and HAM's  F12 (1:1) (Fisher #SH20361), 
10% fetal bovine serum (Fisher), 100 U/ml penicillin and 100 μg/ml streptomycin (together 
referred to as Pen Strep). Cells were maintained at a temperature of 37°C in a humidified 
atmosphere of 95% air and 5% CO2, and media were changed every 3-5 days. Cells were 
trypsinized with 0.25% trypsin/0.1% EDTA, and passages 1-12 were used. For drug treatments 
and experimentation, cells were plated without antibiotics and serum starved for 24 h once they 
had reached 80% confluency. 
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3.2.2 HT-22 murine hippocampal cell line 
 HT-22 cells were cultured and maintained using the same reagents and in the same 
conditions as SH-SY5Y cells. For drug treatments and experimentation, HT-22 cells were seeded 
(at experiment dependent seeding densities) in full growth media for 24 h, after which the cells 
were differentiated in neurobasal media (Gibco, Life Technologies) containing N2 supplement 
and 2 mM L-glutamine for an additional 24 h. Drug treatments were performed in neurobasal 
media.   
3.2.3 Primary hippocampal neuron cell culture  
 Hippocampal and cortical neurons were isolated from embryonic day 17-19 fetuses of 
CD1 mice and placed in cold dissection media (33 mM glucose, 58 mM sucrose, 30 mM 
HEPES, 5.4 mM KCl, 0.44 mM KH2PO4, 137 mM NaCl, 0.34 mM Na2HPO4, 4.2 mM NaHCO3, 
0.03 mM phenol red, pH 7.4, 320-335 mOsm/kg). The hippocampi were separated from the brain 
and digested in 0.25% trypsin/0.1% EDTA for 20 min at 37°C. The resulting cell mixtures were 
plated on poly-D-lysine (PDL) (Sigma) coated 35mm culture dishes and grown at 37°C in a 
humidified atmosphere containing 5% CO2. For cell attachment right after dissection, cells were 
plated in plating media (DMEM, 10% fetal bovine serum (FBS) and 10% horse serum) for 4 h 
which followed a media change to feeding media (Neurobasal media supplemented with B27) 
and feeding media was changed twice per week. In order to inhibit growth of non-neuronal cells, 
FUDR (0.081 mM 5-fluoro-2 deoxyuridine) and 0.2 mM uridine were added 3-4 days after 
plating for 24 h once the cells reached confluency. Drug treatments were performed 10-12 days 
after plating. 
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3.3 Western Blot 
3.3.1 Whole cell lysate preparation 
 For all cell culture experiments, after drug treatment cells were washed with chilled 
phosphate-buffered saline (PBS), and lysed in chilled lysis buffer containing 20 mM Tris-HCl at 
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 30 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM sodium orthovanadate, and 1% Triton X-100; supplemented with Halt 
Protease and Phosphatase Inhibitor  prior to use. In order to solubilize NMDA receptors, the lysis 
buffer for HT-22 cells contained 0.05% SDS in supplement to the Triton X-100 and for 
hippocampal neurons the lysis buffer contained an additional 0.5% SDS in supplement to the 
Triton X-100. Cells were scraped, mechanically homogenized using a syringe and centrifuged at 
14,000 x g for 20 min at 4°C and the supernatants were collected.  
3.3.2 BCA protein assay and sample preparation 
 BCA protein assay (Thermo) was used to quantify concentration of protein in samples. 
Samples were prepared so 25-35 μg total protein could be mixed and heated with 3x loading 
buffer (240 mM Tris-HCl at pH 6.8, 6% w/v SDS, 30% v/v glycerol, 0.02% w/v bromophenol 
blue, 50 mM DTT, and 5% v/v β-mercaptoethanol) for 15 min at 75°C. 
3.3.3 SDS-PAGE and immunodetection  
 Protein samples were loaded into 1.5 mm thick polyacrylamide gel wells. Proteins were 
separated by SDS-PAGE in electrophoresis buffer (25 mM Tris base, 190 mM glycine, 3.5 mM 
sodium dodecyl sulfate), followed by electroblotting of proteins onto nitrocellulose membranes 
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with chilled transfer buffer (25 mM Tris base, 190 mM glycine, 20% v/v methanol) for either 90 
min or 16 h. Membranes were then blocked with 5% non-fat milk in Tris-buffered saline (20 mM 
Tris base, 150 mM NaCl, pH 7.6) plus 0.1% Tween (TBS-T) for 1 h at room temperature or 
overnight at 4 °C, followed by incubation with primary antibody (usually made in blocking 
buffer or just TBS-T) for 1 h at room temperature or overnight at 4 °C. Membranes were washed 
three times with TBS-T, and then incubated with secondary antibody conjugated to horse radish 
peroxidase (HRP) in blocking buffer for 1 h at room temperature (1:5000 for anti-mouse primary 
antibody, 1:10000 for anti-rabbit primary antibody). Membranes were washed three additional 
times with TBS-T. Western chemiluminescent substrate (Luminata Crescendo - Millipore) was 
used to visualize proteins on a Kodak 4000MM Pro Imaging Station. Densitometric analyses on 
blots were performed using Kodak Molecular Imaging software (Carestream Health, USA). 
After imaging, membranes were stripped and re-probed with other appropriate antibodies. 
3.4 MTT Toxicity Assay 
 For neuroprotection assays that required primary hippocampal neurons, isolated 
hippocampal neurons were counted and plated in 96-well plates at 20 x 10
3 
cells/well and grown 
for 10-12 days. After treatment, hippocampal neurons were washed and incubated in feeding 
media for 24 h to allow for cell death after which 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) in an amount equal to 10% of the culture medium volume 
were added to each well and the cells were incubated for an additional 3 h at 37 °C in 5% CO2. 
After incubation, the resulting formazan crystals were solubilized with MTT reagent solution 
(10% Triton X-100 and 0.1 N HCl in anhydrous isopropanol) in each well and the absorbance 
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was recorded at 570 nm and 690 nm. All results are expressed as a percent reduction of MTT 
relative to untreated controls. 
 For neuroprotection assays that required HT-22 cells, a standard seeding density of 2.5 x 
10
3
 cells/well was used in 96-well plates for 24 h and then differentiated for an additional 24 h. 
For experiments that did not require differentiation of HT-22 cells, 2.5 x 10
3
 cells/well were 
seeded in 96-well plates and serum starved for 4 h prior to treatment. After treatment of 
differentiated HT-22 cells (incubating in neurobasal media) MTT was added for 3 h and a read 
out was taken as described above. After treatment of undifferentiated HT-22 cells, a washout was 
performed with serum and phenol red free DMEM (Fisher# SH3027201) after which MTT 
reagent was added for 3 h and a read out was taken.  
3.5 Immunofluorescence 
 Immunofluorescence was performed to look for qualitative and preliminary evidence of 
TrkB receptors in differentiated and undifferentiated HT-22 cells. Briefly, HT-22 cells were 
seeded at 35,000 cells/well in 6 well plates for 24 h and differentiated for an additional 24 h 
(Corning). After differentiation, cells were washed twice in PBS (with calcium and magnesium) 
and pre-fixed with 4% (w/v) paraformaldehyde (Sigma) for 2 min, aspirated and fixed again with 
2% (w/v) paraformaldehyde for 20 min at room temperature pressure. Cells were rinsed twice in 
PBS and then washed in wash buffer (0.1% Bovine Serum Albumin (BSA, Rockland, 
Gilbertsville,PA) in PBS). Cells were then permeabilized and blocked using 0.3 % Triton X-100 
(Sigma) and 10 % FBS all dissolved in PBS for 45 min at room temperature then washed with 
PBS. After blocking, cells were coated with TrkB primary antibody at 1:200 dilution in dilution 
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buffer (PBS, 1% bovine serum albumin (BSA), 0.3% Triton X-100, and 0.01% sodium azide) 
overnight with agitation at 4 °C. Next day, cells were washed twice with PBS and stained with 
secondary antibody (Dylight 488) in dilution buffer at 1:1000 for 1 h. Cells were washed twice in 
PBS and mounted with a cytoplasmic counterstain, CellMask Plasma Membrane Stain Deep 
Red (Invitrogen), for 10 min and visualized on a Zeiss laser scanning confocal microscope LSM 
Z710 (Zeiss, Germany) with 63x oil-based objective. 
3.6 Phase Contrast Microscopy 
 In order to visually assess treatment effects on morphology of differentiated HT-22 cells, 
cells were seeded at a density of 30 x 10
3  
cells/per well in 6-well plates and differentiated for 24 
h. Treatments were performed and images of cells were captured using a 10x objective over an 
inverted phase contrast microscope IX53 (Olympus) attached to a DP25 digital camera 
(Olympus).  
3.7 Statistical analysis 
 Data were analyzed using GraphPad Prism 5.0 (GraphPad Software, USA). Student’s t-
test were used when comparing two data sets, or one-way analysis of variance (ANOVA) with 
Bonferroni’s post hoc test for comparing three or more data sets. Unless otherwise stated, the 
results are presented as mean ± SEM and each n value denotes independent experiments. For 
graphs,  *=p < 0.05, **=p<0.01 and ***=p<0.001.  
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Chapter 4: Results 
4.1 Short-term LP 12 treatment induces changes in PDGFRβ and TrkB-FL 
expression and activity in primary hippocampal neurons 
             
 Short-term time course experiments of 0.25 to 4 h of 300 nM LP 12 treatments were 
performed in primary hippocampal neurons. The concentration of 300 nM LP 12 was previously 
shown to maximally increase PDGFβ receptor expression at 24 h [103]. This concentration also 
resulted in a significant downregulation of the 5-HT7 receptor [103]. The aggregate time course 
data indicated that LP 12 caused a sustained phosphorylation of PDGFβ receptors at tyrosine 
1021 (Y1021) between 2 and 4 h (Figure 4A). Total PDGFβ receptor expression was only 
significantly elevated above baseline at 2 h (Figure 4B). In addition to PDGFβ receptor 
signalling, assessment of TrkB receptor phosphorylation at tyrosine 816 (Y816) revealed 
significant increases at 2 h and 4 h (Figure 4C) where TrkB expression was also increased at 2 h 
and 3 h but not 4 h (Figure 4D). Using the same membranes from the time course, changes in 
expression of NR2B subunits, PLCγ1, 5-HT7 receptor, as well as Akt phosphorylation at 
threonine 308 (Thr308) were also measured. Given the increased phosphorylation of Y1021 
between 2 h and 4 h, along with the elevated Y816 phosphorylation at 2 h, it was expected that i) 
NR2B total expression be reduced (Figure 5A) ii) PLCγ1 expression be elevated at 2 h and 4 h 
(Figure 5B), and iii) at least one downstream signalling protein be active; this was the case with 
pAkt Thr308 (Figure 5D). Changes in 5-HT7 receptor expression revealed a significant increase 
in expression at 1 h followed by a sustained return to baseline until 4 h (Figure 5C).       
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Figure 5. Short term 5-HT7 receptor activation increases PDGFRβ and TrkB-FL 
expression and phosphorylation in hippocampal neurons.  
Cultured hippocampal neurons were treated with selective 5-HT7 receptor agonist LP 12 (300 nM) for 
0.25 h to 4 h. (A, B) The phosphorylation of the PDGFβ receptors was determined using an anti-phospho-
Y1021 PDGFβ receptor antibody and was normalized to total PDFGβ receptor expression (n = 4), The 
level of PDGFβ receptor expression is displayed as a fold change vs. vehicle-treated neurons. and was 
normalized to β-actin (n = 4). (C, D) The phosphorylation of the TrkB-FL receptor was determined using 
an anti-phospho-Y816 TrkB receptor antibody and was normalized to total TrkB-FL receptor expression 
(n = 4), the level of TrkB-FL receptor expression is displayed as a fold change vs. vehicle-treated 
neurons. and was normalized to β-actin (n = 4).  *p<0.05, ANOVA analysis with Bonferroni's post-hoc 
test. E) Representative Western blots for Y1021, PDGFβ receptor, Y816, TrkB-FL, and β-actin.    
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Cultured hippocampal neurons were treated with selective 5-HT7 receptor agonist LP 12 (300nM) for 
0.25 h to 4 h. (A) The level of NR2B subunit receptor expression is displayed as a fold change vs. 
vehicle-treated neurons. and was normalized to β-actin (n = 4). (B) the level of PLCγ1 expression is 
displayed as a fold change vs. vehicle-treated neurons and was normalized to β-actin (n = 4). (C) the level 
of 5-HT7 receptor expression is displayed as a fold change vs. vehicle-treated neurons and was normalized 
to β-actin (n = 5).  (D) The phosphorylation of Akt at threonine 308 (pAkt Thr308) was determined using 
an anti-phospho-Akt Thr308 antibody and was normalized to total Akt expression (n = 4), *p<0.05, 
**p<0.01, ANOVA analysis with Bonferroni's post-hoc test. E) Representative Western blots for NR2B, 
PLC γ1, 5-HT7 receptor, pAkt Thr308, Akt and β-actin.    
Figure 6. Short-term activation of 5-HT7 receptors increases PLCγ1 expression and Akt 
phosphorylation which reduces NR2B expression in hippocampal neurons.  
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 To determine if the changes in expression and phosphorylation of TrkB-FL and PDGFβ 
receptor were indeed 5-HT7 receptor dependent in primary hippocampal neurons, the selective 5-
HT7 receptor antagonist, SB 258719 (5 µM), was applied 30 min prior to LP 12 treatment for 2 h 
and 4 h treatments only (due to primary neuronal culture constraints not all time points could be 
assessed). With 2 h agonist exposure, SB 258719 blocked increases in TrkB-FL expression and 
Y816 phosphorylation (Figure 6A & B), as well as blocking increases in PLCγ1 expression 
(Figure 6C) and pAkt Thr308 (Figure 6E). The LP 12 induced reduction in NR2B subunit was 
not blocked by SB 258719 at 2 h (Figure 6D).       
 At 4 h of LP 12 treatment, SB 258719 blocked the increases in TrkB Y816 and PDGFRβ 
Y1021 phosphorylation, respectively (Figure 7A & B). Increases in PLCγ1 expression and pAkt 
Thr308 phosphorylation were also blocked by SB 258719 (Figure 7C & E). At 4 h of LP 12 
treatment NR2B levels were decreased below baseline and SB 258719 blocked this from 
occurring in the presence of LP 12 (Figure 7D). Taken together, these results suggest that the 
observed changes in protein and phosphorylation levels induced by LP 12 are indeed 5-HT7 
receptor dependent. 
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Cultured hippocampal neurons were treated with selective 5-HT7 receptor agonist LP 12 (300 nM), 5 µM 
SB 258719, or both where SB was treated 30min prior to LP 12 treatment for 2 h. (A, B) The 
phosphorylation of the TrkB-FL receptor was determined using an anti-phospho-Y816 TrkB receptor 
antibody and was normalized to total TrkB-FL receptor expression (n = 4), the level of TrkB-FL receptor 
expression is displayed as a fold change vs. vehicle-treated neurons and was normalized to β-actin (n = 4). 
(C, D, E) The level of PDGFβ receptor expression (n=5), PLCγ1 expression (n=5) and NR2B expression 
(n=6)  are displayed as a fold change vs. vehicle-treated neurons. and were normalized to β-actin. (F) The 
phosphorylation of Akt at threonine 308 (pAkt Thr308) was determined using an anti-phospho-Akt 
Thr308 antibody and was normalized to total Akt expression (n = 6), *p<0.05, **p<0.01, ANOVA 
analysis with Bonferroni's post-hoc test. G) Representative Western blots for Y816, TrkB-FL, PDGFβR, 
PLC γ1, NR2B, pAkt Thr308, Akt and β-actin.    
Figure 7. Two hour changes in TrkB-FL and PDGFR expression and phosphorylation are 5-HT7 receptor 
dependent in hippocampal neurons  
See description on next page. 
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Cultured hippocampal neurons were treated with selective 5-HT7 receptor agonist LP 12 (300 nM), 5 µM 
SB 258719, or both  where SB was treated 30 min prior to LP 12 treatment for 4 h. (A, B) The 
phosphorylation of the TrkB-FL receptor was determined using an anti-phospho-Y816 TrkB receptor 
antibody and was normalized to total TrkB-FL receptor expression (n = 6). The phosphorylation of the 
PDGFβ receptors was determined using an anti-phospho-Y1021 PDGFβ receptor antibody and was 
normalized to total PDFGβ receptor expression (n = 6). (C, D) The level of PLCγ1 expression (n=6) and 
NR2B expression (n=6)  are displayed as a fold change vs. vehicle-treated neurons. and were normalized 
to β-actin. (E) The phosphorylation of Akt at threonine 308 (pAkt Thr308) was determined using an anti-
phospho-Akt Thr308 antibody and was normalized to total Akt expression (n = 6), *p<0.05, **p<0.01, 
ANOVA analysis with Bonferroni's post-hoc test. F) Representative western blots for Y816, TrkB-FL, 
Y1021, PDGFβR, PLC γ1, NR2B, pAkt Thr308, Akt and β-actin.    
Figure 8. Four hour changes in TrkB-FL and PDGFR expression and phosphorylation are 5-HT7 
receptor dependent in hippocampal neurons 
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4.2 Short-term activation of 5-HT7 receptors is neuroprotective against NMDA 
excitotoxicity in hippocampal neurons 
  
 Given the rapid changes in TrkB and PDGFβ receptor expression and phosphorylation at 
2 h and 4 h and the decreased NR2B subunit expression, we hypothesized that LP 12 would 
protect primary hippocampal neurons from NMDA/glycine induced excitotoxicity, similarly to 
what was previously shown at 24 h [103]. MTT toxicity assays were performed in hippocampal 
neurons which were pre-treated with 300 nM LP12 for either 2 or 4 h followed by NMDA (100 
µM) and co-agonist, glycine (1 µM), to induce NMDA excitotoxicity. As the hypothesis is that 
LP 12's effects are RTK-dependent, specifically, PDGFβ receptor-dependent, 5 µM STI-571 
(imatinib mesylate) was applied 30 min prior to LP 12 treatment. As a positive control, 10 ng/mL 
PDGF-BB was applied 10 min prior to NMDA/glycine insult as it would demonstrate direct 
neuroprotective effects of PDGFβ receptor activation against excitotoxicity. Hippocampal 
neurons pre-treated with LP 12 for 2 or 4 h remained more viable than neurons in the NMDA 
alone group (Figure 8 A & D). Additionally, the extent of neuroprotection was reduced in 
neurons pre-treated with STI-571 suggesting that the neuroprotection against excitotoxicity was 
likely due to LP 12-induced increases in signalling activity of RTKs like the PDGFβ receptor. 
Finally, neurons that were treated with PDGF-BB directly were protected as previously 
described at Beazely lab [89, 103].             
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Hippocampal cultures were pre-treated with vehicle or 300 nM LP 12 for 2 h or 4 h followed by 
100 μM NMDA/1 μM glycine for 10 min. To determine if the neuroprotective effects of the 5-
HT7-receptor agonist required PDGFβ receptor kinase activity, cultures were co-pre-treated with 
5 μM STI-571 (imatinib mesylate) followed by the same LP 12 pre-treatment and respective 
NMDA/glycine insult. For the PDGF-BB + NMDA bar, 10 ng/mL PDGF-BB was added for 10 
min prior to respective NMDA/glycine treatment. The number of viable cells were determined 
24 h later by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, n=3 *p 
< 0.05, **p < 0.01 ANOVA analysis with Bonferroni’s post-test (for all LP 12 bars, second last 
bar is a single, representative experimental result). 
Figure 9. Two and four hours LP 12 pre-treatment protects hippocampal neurons from NMDA 
excitotoxicity 
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4.3 Investigating the susceptibility of differentiated HT-22 cells to NMDA mediated 
excitotoxicity          
 
 Amongst researchers studying neuronal excitotoxicity and ionotropic glutamate receptors 
the consensus is that cell lines of neuronal origin typically do not possess functional ionotropic 
glutamate receptors [106]. Many studies to date have attempted to differentiate cell lines with 
different growth medias, growth factors, and agents like retinoic acid that collectively act at the 
transcriptional level to induce distinct phenotypic changes in cell lines (however these changes 
do not always have functional outcomes) [107]. As far as ionotropic glutamate receptors in cell 
lines are concerned, mRNA transcripts for the NR1 subunit in cell lines like PC12 (adrenal 
medulla) [113], SH-SY5Y (human neuroblastoma) [108], and oligodendroglial lineage cells 
[113] have been reported but no evidence of NR2 subunit mRNA or protein has been found in 
these cell lines.           
 Two recent publications have made a direct claim that differentiating immortalized 
mouse hippocampal neuronal HT-22 cells renders them sensitive to glutamate excitotoxicity by 
inducing expression of NMDA receptors [109, 110]. These papers show evidence of NR1 
subunits expressing after differentiation (other subunits were not assessed) and the NMDA 
receptor channel blockers MK-801 and memantine exerted neuroprotection against 50 µM 
glutamate or 1 mM homocysteine over 24 h (concentrations typically used in neuronal 
excitotoxicity experiments in primary neuronal cells) [116]. It is widely accepted across 
literature that HT-22 cells do not express functional ionotropic glutamate receptors and are 
susceptible to death only after high doses of glutamate (1 mM-10 mM) over several hours 
through a mechanism independent of ionotropic glutamate receptors (see recent review [113]). 
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We decided to investigate the possibility of HT-22 cells expressing NMDA receptors and being 
susceptible to NMDA excitotoxicity upon differentiation as reported in a single isolated 
publication [116]. 
4.3.1 HT-22 Cells are susceptible to NMDA and glutamate toxicity in a dose and 
time dependent manner 
  
 The susceptibility of undifferentiated and differentiated HT-22 cells to NMDA and 
glutamate was tested using the MTT assay. First, in accordance with literature, we found that    
24 h incubation with high millimolar concentrations of glutamate (L-glutamic acid) in 
undifferentiated HT-22 cells significantly reduced cell viability (EC50 5.8 ±0.37mM) (Figure 
9A). In contrast, NMDA was not able to exert any significant cytotoxic effects in 
undifferentiated HT-22 cells (Figure 9A). HT-22 cells that were differentiated for 24 h in 
neurobasal media and N2 supplement displayed a different sensitivity to 24 h treatments with 
both glutamate and NMDA. Both glutamate and NMDA significantly reduced cell viability in a 
concentration dependent manner in differentiated cells; EC50 of ~1.36 ± 0.14mM and ~0.98 ± 
0.09 mM, respectively (Figure 9B). Interestingly, the EC50 for glutamate induced reduction in 
cell viability of differentiated cells is more than ten folds higher than reported by He et al. [116].  
 Using the EC50 values from Figure 9B, further MTT assays were used to assess if short-
term (10 min to 4 h) glutamate or NMDA treatment could reduce cell viability in differentiated 
HT-22 cells. Differentiated HT-22 cells were exposed to 2 mM glutamate or 1 mM NMDA (with 
10 µM glycine co-treatment) over a time course of 10 min to 4 h followed by MTT reagent 
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application. Between 2 and 4 h, both NMDA and glutamate significantly reduced cell viability, 
though not below 50% as was the case with 24 h treatments (Figure 9C). 
 An important question left to be answered was whether if the sensitivity of differentiated 
HT-22 cells to glutamate and NMDA was dependent on the amount of time the cells were 
allowed to differentiate. Time course experiments were performed using the MTT assay to assess 
if HT-22 cells were still sensitive to 4 h NMDA and glutamate treatment when differentiated for 
either 6 h, 12 h, or 48 h. The time course revealed that 1 mM NMDA and 2 mM glutamate 
treatment for 4 h resulted in the greatest reduction in cell viability in HT-22 cells that were 
differentiated for 24 h (Figure 9D) but further differentiation (48 h) did not result in additional 
toxicity.            
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(A) Undifferentiated HT-22 cells were treated with 0.1 mM to 10 mM glutamate or NMDA (with 10 µM 
glycine) for 24 h. (B) Differentiated HT-22 cell were treated with 0.01 mM to 2 mM glutamate or NMDA 
(with 10 µM glycine) for 24 h. (C) To assess if a shorter exposure with NMDA and glutamate would 
exert any toxic effects on differentiated HT-22 cells, 1 mM NMDA (with 10 µM glycine) or 2 mM 
glutamate was applied for 10 min to 240 min (1440 h time point obtained from B). (D) HT-22 cells were 
differentiated for 6h , 12 h, 24 h or 48 h and treated with 1 mM NMDA (with 10 µM glycine) or 2 mM 
glutamate for 4 h.    
The number of viable cells were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assays. All experiments were performed twice in quadruplets. 
Figure 10. Differentiation renders HT-22 cells susceptible to NMDA and glutamate toxicity 
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4.3.2 Investigating the presence of functional NMDARs and RTKs in differentiated 
HT-22 cells  
 
 MTT toxicity assays showed a clear trend towards differentiation induced phenotypic 
changes in the HT-22 cell line. Literature to date on undifferentiated HT-22 cells largely shows 
that high concentrations of glutamate causes the failure of the cystine/glutamate antiporter which 
brings about ROS mediated oxidative stress; a non-ionotropic glutamate receptor dependent form 
of glutamate cytotoxicity [106]. The next line of experiments in HT-22 cells investigated if i) 
differentiation for 24 h causes expression of functional NR1 and NR2 subunits, and ii) the 
differentiated cells possess functional PDGFRβ and TrkB-FL receptors. 
 Initial Western blot screening comparing undifferentiated and differentiated HT22 cells 
revealed conclusive presence of NR1 subunit, TrkB-FL and its truncated isoforms (TrkB-Shc, 
TrkB-T1), PDGFβ receptor, and 5-HT7 receptors in both types of HT-22 cells (Figure 10). 
Interestingly, no conclusive evidence of NR2B or NR2A subunits expressing in either type of 
HT-22 cells was obtained, although densitometry analysis for these blots did result in a net 
positive intensity where extremely faint intensity bands were noticed particularly for the NR2B 
subunit in differentiated HT-22 cells (Figure 10).    
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Differentiated or undifferentiated HT-22 cells were lysed and evaluated by Western blot analysis 
(n=3). 
 
  
 Given no conclusive evidence of NR2 subunits was found through Western blot 
characterization, a number of reasons pertinent to methodical issues have been suggested in the 
discussion section of this document. The NR1 subunits were robustly expressed in both 
differentiated and undifferentiated cells, as has previously been reported [106].   
 Evidence of functional TrkB-FL or any of its isoforms has not been reported to date in 
HT-22 cells [94] unless artificially transfected  [111]. The distinct finding of TrkB-FL receptors 
Figure 11 NMDARs and RTKs in differentiated and undifferentiated HT-22 cells  
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and its isoforms in both differentiated and undifferentiated cells warranted an investigation into 
their functionality. First, preliminary immunohistochemistry experiments were performed to 
visually detect the presence of TrkB receptors in undifferentiated and differentiated HT-22 cells. 
The presence of TrkB receptors was easily detected in both differentiated and undifferentiated 
cells under a confocal microscope (Figure 11). Differentiated HT-22 cells were treated with a 
range of concentrations of BDNF for 10 min, lysed and subject to western blotting. 
Differentiated cells exerted no response to BDNF treatment as measured by TrkB-Y816 
phosphorylation, TrkB-FL expression, ERK phosphorylation and Akt Thr308 phosphorylation 
(Figure 11). This key experiment suggested the possibility of HT-22 cells expressing non-
functional TrkB receptors, although given there was no positive control it is also possible the 
treatment time of 10 min may not have been enough to phosphorylate TrkB-FL receptor. 
 The functionality of PDGFβ receptors was also assessed by applying increasing 
concentrations of the natural ligand PDGF-BB for 10 min in differentiated HT-22 cells. Western 
blot analysis clearly revealed that PDGFβ receptors were active and functional in this cell line 
given the sharp (and large) increases in tyrosine 1021, ERK, and Akt Thr 308 phosphorylation, 
respectively (Figure 12A, C, and D). Upon ligand mediated activation of the tyrosine 1021 site, 
the total expression of PDGFβ receptors plummeted well below baseline (Figure 12B) and 
interestingly, the expression of NR1 subunit was significantly reduced with 10 ng/mL PDGF-BB 
application (Figure 12E).            
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HT-22 cells were either left undifferentiated (R panel) or differentiated for 24 h (L panel). Cell cytoplasm 
were directly stained with deep red CellMask plasma membrane stain, and the TrkB receptor was 
detected using an anti-TrkB receptor antibody and a secondary antibody conjugated to Dylight 488 
(green). The images displayed are representative of three independents wells per condition. *Imaging was 
performed by Ding Wen (Roger) Chen, Foldvari Lab, University of Waterloo School of Pharmacy.  
 
 
 
 
 
 
 
 
Figure 12. Immunohistochemistry reveals presence of TrkB receptors in differentiated and undifferentiated 
HT-22 cells 
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Differentiated HT-22 cells were treated with 0.1 ng/mL to 25 ng/mL BDNF for 10 minutes and subject to 
Western blotting. (A, B) The phosphorylation of the TrkB-FL receptor was determined using an anti-
phospho-Y816 TrkB receptor antibody and was normalized to total TrkB-FL receptor expression (n = 3). 
TrkB-FL receptor expression is displayed as fold change vs. vehicle treated HT-22 cells and normalized 
to β-actin. (C) The phosphorylation of ERK was determined using the anti-pERK1/2 antibody and was 
normalized to total ERK expression (n=3). (D) The phosphorylation of Akt at threonine 308 (pAkt 
Thr308) was determined using an anti-phospho-Akt Thr308 antibody and was normalized to total Akt 
expression (n = 3). ANOVA analysis with Bonferroni's post-hoc test. (E) Representative western blots for 
Y816, TrkB-FL, pERK, ERK,  pAkt Thr308, Akt, NMDA subunits and β-actin are shown.    
Figure 13. TrkB receptors in differentiated HT-22 cells are not responsive to BDNF 
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Differentiated HT-22 cells were treated with 0.1 ng/mL to 10 ng/mL BDNF for 10 minutes and subject to 
western blotting. (A, B) The phosphorylation of the PDGFβ receptors was determined using an anti-
phospho-Y1021 PDGFβ receptor antibody and was normalized to total PDFGβ receptor expression (n = 
3), where total PDGFβ receptor expression is displayed as fold change vs. vehicle and normalized to β-
actin (n=3). (C) The phosphorylation of ERK was determined using the anti-pERK1/2 antibody and was 
normalized to total ERK expression (n=3). (D) The phosphorylation of Akt at threonine 308 (pAkt 
Thr308) was determined using an anti-phospho-Akt Thr308 antibody and was normalized to total Akt 
expression (n = 3). (D) The expression of NR1 subunit is displayed as fold change vs. vehicle and 
normalized to β-actin (n=3). *p<0.05, **p<0.01, ANOVA analysis with Benferroni's post-hoc test. (E) 
Representative western blots for Y1021, PDGFRβ, pERK, pAkt Thr308, NMDAR subunits, and β-actin 
are shown.    
Figure 14. Differentiated HT-22 cells express functional PDGFβ receptors 
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4.4 Short-term LP 12 treatment increases PDGFβ receptor signalling activity in 
differentiated HT-22 cells  
 
 Even though no evidence of functional ionotropic NMDA receptors was found in 
differentiated HT-22 cells, a rapid decrease of the NR1 subunit expression was seen with 10 
ng/mL PDGF-BB application (Figure 12E). Vasefi et al. reported a decrease in NR1 subunit 
expression with 24 h LP 12 application in primary hippocampal neurons [103], but Beazely et 
al., reported no significant changes in NR1 subunit expression with 10 min PDGF-BB 
application to CA1 hippocampal neurons [89]. Given the presence of functional 5-HT7 receptors, 
PDGFβ receptor and potentially a small subset of active NMDA receptors in the differentiated 
cell line, the next step was to investigate if LP 12 could induce short-term (1-4 h) changes in 
Y1021 phosphorylation in differentiated HT-22 cells.  
 A comprehensive time course with LP 12 was not performed in differentiated HT-22 
cells based on strong evidence that 300 nM LP 12 treatment for 4 h significantly activates the 
PDGFRβ -Y1021 site in primary hippocampal neurons (Figure 4A), primary cortical cultures 
(supplementary Figure 18C & D) and SH-SY5Y neuroblastoma cells (supplementary Figure 18A 
& B). Differentiated HT-22 cells were treated with a range of concentrations of LP 12 for 4 h to 
see if 300 nM would be the ideal concentration for activating 5-HT7 receptors as measured by 
phosphorylation of Y1021, ERK, Akt Thr308 and PLCγ1, respectively. Compared to other 
concentrations, 300 nM LP 12 considerably increased Y1021, PLCγ1, ERK. and Akt Thr308 and 
phosphorylation, respectively (Figure 13 A, B, D, E). Interestingly, 5-HT7 receptor expression 
was well below baseline with 300 nM LP 12 (Figure 13C).         
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Differentiated HT-22 cells were treated with 50 nM to 1000 nM LP 12 for 4 h and subject to Western 
blotting. (A) The phosphorylation of the PDGFβ receptors was determined using an anti-phospho-Y1021 
PDGFβ receptor antibody and was normalized to total PDFGβ receptor expression (n= 4) (B) The 
phosphorylation of the pPLCγ1 was determined using an anti-phospho-PLCγ1 antibody was normalized 
to total PLCγ1 expression (n=4). (C) The expression of 5-HT7 receptor is displayed as fold change vs. 
vehicle and normalized to β-actin (n=4). (D) The phosphorylation of ERK was determined using the anti-
pERK1/2 antibody and was normalized to total ERK expression (n=4). (E) The phosphorylation of Akt at 
threonine 308 (pAkt Thr308) was determined using an anti-phospho-Akt Thr308 antibody and was 
normalized to total Akt expression (n=4). *p<0.05, **p<0.01, ANOVA analysis with Bonferroni's post-
hoc test. (F) Representative western blots for Y1021, PDGFRβ, pPLCγ1, PLCγ1, pERK, ERK, pAkt 
Thr308, Akt, 5-HT7 receptor, and β-actin. 
Figure 15. Four hour LP 12 treatment in differentiated HT-22 cells increasing PDGF receptor signalling 
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4.5 Short-term 5-HT7 receptor activation is neuroprotective against NMDA 
excitotoxicity in differentiated HT-22 cells 
 
 Some preliminary MTT assays performed in undifferentiated HT-22 cells showed PDGF-
BB mediated neuroprotection against 3 h hydrogen peroxide insult, as well as 8 h glutamate 
insult (see supplementary Figure 19A & B), suggesting PDGFβ receptor activation in HT-22 
cells is indeed effective against oxidative stress; a finding that has recently been validated [112]. 
The next aim was to determine if changes in PDGFβ receptor signalling that was seen with 5-
HT7 receptor activation in differentiated HT-22 cells (Figure 13) would be neuroprotective 
against a 4 h NMDA insult. MTT assays were performed on differentiated HT-22 cells that were 
pre-treated with 300 nM LP 12 for 4 h after which an excitotoxic insult of 1 mM NMDA/10 µM 
glycine was given to cells for an additional 4 h. In order to determine if any neuroprotective 
activity would be due to PDGFβ receptor tyrosine kinase activity, 5 µM of a selective tyrosine 
kinase inhibitor, AG 1296, was applied 30 min prior to LP 12. Additionally, any effects of the 
NMDA receptor ion channel blocker, MK-801, against NMDA excitotoxicity was also assessed 
by applying 20 µM, 30 min prior to NMDA/glycine insult.  
 LP 12 pre-treatment in differentiated HT-22 cells significantly protected cells against 
NMDA where the neuroprotection was dependent on the kinase activity of the PDGFβ receptor 
as AG 1296 co-treatment with LP 12 blocked any survival effects (Figure 14). Interestingly, 
these assays also revealed that cells treated with MK-801 prior to NMDA insult were 
significantly more viable than cells treated with NMDA alone (Figure 14), further complicating 
explanations to the negative findings of NR2 subunits in differentiated cells.      
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Differentiated HT-22 cells were pre-treated with vehicle or 300 nM LP 12 for 4 h followed by 1 mM 
NMDA/10 μM glycine for an additional 4 h. To determine if the neuroprotective effects of the 5-HT7-
receptor agonist required PDGFβ receptor kinase activity, cultures were co-pre-treated with 5 μM AG 
1296 followed by the same LP 12 pre-treatment and respective NMDA/glycine insult. NMDA receptor 
ion channel blocker, MK 801 (20 µM) was treated 30 min prior to NMDA/glycine insult. The number of 
viable cells were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay, n=3 *p < 0.05, **p < 0.01 ANOVA analysis with Bonferroni’s post-test. Phase-contrast 
photomicrographs of representative conditions are shown, bottom right image is an example of 2mM 
glutamate cytotoxicity after 4 h; images obtained with 10x objective; scale bars represent 50 µM. 
Figure 16. LP 12 is neuroprotective against NMDA excitotoxicity in differentiated HT-22 cells 
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 The mechanism by which LP 12 can keep its pro-survival activity sustained over a course 
of 8 h and prove to be neuroprotective against NMDA had to be investigated via Western blot 
analysis. Differentiated cells were pretreated with 4 h of LP 12 or co-pretreated with SB 258719 
(30 min prior to LP 12), both in the presence or absence of a 4 h application of NMDA. Given 
the longer time frame of this experiment the data is hard to interpret from the perspective of 5-
HT7 receptor mediated activation of PDGFβ receptor signalling, however it does show 
conclusively that in the NMDA insult alone group there is elevated expression of PDGFβ 
receptors, 5-HT7 receptors, and the NR1 subunit (Figure 15 A, B and C). To date, it is well 
understood that the PDGFβ receptor system is up-regulated in vivo as a response to ischemia but 
no study has evaluated 5-HT7 receptor mRNA or expression levels during an excitotoxic insult. 
The activity of tyrosine 1021 was found to be below baseline in all conditions that contained 
NMDA (data not shown), but PDGFβ receptor expression was elevated in all these conditions 
except for SB 25/LP 12/NMDA condition (Figure 15A), perhaps suggesting a compensatory 
mechanism in PDGFβ receptor signalling during excitotoxicity. Last, the elevated levels of 
phosphorylated Akt in the LP+NMDA group (Figure 15D) provides some indication of pro-
survival signalling being sustained until the end of the 8 h treatment.  
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Differentiated HT-22 cells were treated with 300 nM LP 12 for 4 h or co-pretreated with 5 µM SB 
258719, 30 min prior to LP 12 treatment. The cells were then subject to 4 h insult of 1 mM NMDA/ 10 
µM glycine and subject to Western blotting. (A) The expression of PDGFβ receptor is displayed as fold 
change vs. vehicle and normalized to β-actin (n=3). (B) The expression of NR1 subunit is displayed as 
fold change vs. vehicle and normalized to β-actin (n=3). (C) The expression of 5-HT7 receptor is 
displayed as fold change vs. vehicle and normalized to β-actin (n=3). (D) The phosphorylation of Akt at 
threonine 308 (pAkt Thr308) was determined using an anti-phospho-Akt Thr308 antibody and was 
normalized to total Akt expression (n=3). *p<0.05, **p<0.01 relative to control, ANOVA analysis with 
Bonferroni's post-hoc test. (F) Representative Western blots for PDGFRβ, NR1, 5-HT7, pAkt Thr308, 
Akt, and β-actin. 
Figure 17. 5-HT7 receptor, PDGFβ receptor and NR1 subunit expression is elevated during NMDA 
excitotoxicity 
- 
- 
+ 
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4.6 Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) SH-SY5Y cells were treated with 300 nM LP 12 for 0.25 h to 4 h and subject to Western blotting. 
The phosphorylation of the PDGFβ receptors was determined using an anti-phospho-Y1021 PDGFβ 
receptor antibody and was normalized to total PDFGβ receptor expression (n= 4), (B) Representative 
blots for A. (C) Primary cortical cultures were treated on the 10
th
 day in vitro with 300 nM LP 12 for 0.25 
h to 4 h and subject to Western blotting. The phosphorylation of the PDGFβ receptors was determined 
using an anti-phospho-Y1021 PDGFβ receptor antibody and was normalized to total PDFGβ receptor 
expression (n= 5). (D) Representative western blots for C. *p<0.05, **p<0.01 relative to control, 
ANOVA analysis with Benferroni's post-hoc test. 
Figure 18. Short-term LP 12 time courses in SH-SY5Y cells and primary cortical cultures 
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(A) Undifferentiated HT-22 cells were pre-treated with a 10 min application of 10 ng/mL PDGF-BB or 
co-pretreated with 5 µM of a PDGFRβ kinase inhibitor, AG 1296, thirty min prior to LP 12 treatment. 
Cells were then subject to 3 h treatment with 200 µM H2O2.  (B) Undifferentiated HT-22 cells were pre-
treated with a 10 min application of 10 ng/mL PDGF-BB or co-pretreated with 5 µM of a PDGFRβ 
kinase inhibitor, AG 1296, thirty min prior to LP 12 treatment. Cells were then subject to 5 mM glutamate 
insult for 8 h.  
The number of viable cells were determined in both (A) and (B) by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, n=3 *p < 0.05, **p < 0.01 ANOVA analysis with 
Bonferroni’s post-test.  
 
 
 
 
Figure 19. PDGF-BB protects against glutamate and H2O2 oxidative stress in undifferentiated HT-22 cells 
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Chapter 5: Discussion 
 The results presented in this thesis have added a different dimension to the findings of 
Vasefi et al., who discovered a novel pathway by which PDGFβ receptors can be activated in a 
ligand-independent manner using 5-HT7 receptor agonists. The ultimate aim of this project was 
to ameliorate the effects of neuronal excitotoxicity by achieving the same GPCR-RTK-NMDAR 
cross-talk with short-term exposure to 5-HT7 receptor agonists. The following sections will 
summarize and provide commentary on the results of this project.  
5.1 5-HT7 receptor activation increases neurotrophic signalling in neurons  
 The first objective of this project was to collect evidence of significant 5-HT7-
PDGFRβ/TrkB-NMDAR cross-talk pathway occurring with short-term agonist (LP 12) 
exposure, across different cell models. The most compelling evidence of this pathway came from 
1 h to 4 h treatment of primary hippocampal neurons where the PDGF system was activated 
between 2 and 4 h as levels of Y1021 phosphorylation were maximal at 4 h (Figure 5A). 
Additionally, in primary hippocampal neurons, the selective 5-HT7 receptor inhibitor, SB 
258719, blocked increases in Y1021 phosphorylation at 4 h, suggesting the mechanism was 5-
HT7 receptor-dependent. In differentiated HT-22 cells, SH-SY5Y cells, and primary cortical 
neurons, 5-HT7 receptor activation also increased PDGFβ receptor phosphorylation and its 
subsequent downstream activity at 4 h (Figure 15, supplementary Figure 18 A-D). Interpreting 
the results of the short-term time course (15 min to 4 h) in this project and that of the long-term 
time course performed by Vasefi et al. [57] suggests that the PDGF neurotrophic system begins 
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to elevate in activity around 2 h of LP 12 incubation and peaks at 4 h, 8 h and again at 24 h 
(Figure 20A).  In contrast, LP 12 treatment in primary hippocampal neurons showed increased 
TrkB receptor activity at 2 h and then again at 4 h where TrkB receptor expression was also 
elevated at 2 and 3 h but not 4 h (Figure 5 C & D). Samarajeewa et al., previously showed that 
TrkB phosphorylation and expression is elevated significantly above baseline with 24 h LP 12 
treatment in primary cortical neurons, retinal ganglion cell line (RGC-5), and SH-SY5Y cells 
[65]. The short-term time courses of Samarajeewa et al., in SH-SY5Y cells only revealed 
elevated TrkB expression but not Y816 phosphorylation between 1 h and 2 h whereas in RGC-5 
cells both TrkB expression and phosphorylation were elevated in the same time frame [65]. 
Collectively, it is possible that short-term (2 to 4 h) as well as long-term (24 h) 5-HT7 activation 
also elevates TrkB receptor activity above baseline however time points between 4 h and 24 h 
are yet to be investigated (Figure 20B). 
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Schematic representing time course of 5-HT7 receptor activation as a function of increased PDGFRβ and 
TrkB activity 
           
 Ligand-independent intracellular activation of RTKs by GPCRs is usually coined the 
term "transactivation", an event that is frequently reported in literature to be acute, and transient 
in nature. One of the first, and best, studies to have demonstrated transactivation involve D2-
class dopamine receptor transactivation of PDGFβ receptors [53]. In this study, the activation of 
either D2L (long isoform) or D4 dopamine receptors in Chinese hamster ovary (CHO) cells 
results in the phosphorylation of ERK1/2 downstream of PDGFβ receptors that were 
transactivated in a Gαi/o and Src-dependent manner [53]. Another prominent example includes 5-
HT (serotonin) induced phosphorylation of ERK1/2 as well as PDGFβ and TrkB receptor 
phosphorylation in SH-SY5Y cells where all phosphorylation events depend on NADPH oxidase 
but only the RTK phosphorylation is dependent on ROS [55]. Current literature points to a 
myriad of factors that are involved in transactivation which occurs in many in vitro models, these 
Figure 20. Time course of 5-HT7 receptor activation and PDGFRβ and TrkB neurotrophic activity 
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include: timing and choice of ligand, several common effector proteins involved between the 
GPCR and the RTK, role of β-arrestins in enhancing or downregulating the transactivation, 
dimerization of RTKs and localization between the GPCR and the RTK [113].  
 Unlike transactivation that occurs rapidly and only lasts a few minutes, results of this 
project adds to the growing number of studies that report a late onset yet longer lasting form of 
ligand independent activation of RTKs via GPCRs. This particular process is an exception to the 
"acute RTK transactivation rule" where for instance, activation of adenosine receptors or 
D1dopamine receptors in striatal neurons (using 1 µM of a D1/D5 agonist SKF38393) increases 
TrkB receptor phosphorylation after 3 h where phosphorylation remains elevated up to 6 h [114].  
Additionally, in CHO cells D2L and D3 dopamine receptors increased Akt and GSK-3β 
phosphorylation for more than 2 h after a 10 min treatment with dopamine, a process that was 
dependent on the RTK insulin like growth factor-1 (IGF-1) receptor [115]. As shown in Figure 
20 it is clear that short-term and long-term activation of 5-HT7 receptor activation by selective 
agonists leads to ligand independent increases in PDGFβ and TrkB receptor activity that has 
physiologically relevant consequences as measured by increased PLCγ1 levels (Figure 7D and 
8C), decreased NR2B levels (Figure 7E and 8D) and increased Akt phosphorylation (Figure 7F 
and 7E). The exact intracellular signalling components that lead to short-term and long-term 
activation of PDGFβ and TrkB receptors via 5-HT7 receptors are currently unknown and should 
be subject to immediate investigation. As far as this particular cross-talk pathway is concerned, 
some key questions remain unanswered thus far: i) why is it that 5-HT7 receptor dependent 
ligand-independent elevation in neurotrophic systems occur in two different time periods? ii) 
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Unlike at 24 h, why do increases in PDGFβ and TrkB receptor activity not overlap over the 
short-term time course i.e., why don't they occur at the same time points?      
 The mechanistic questions regarding the role of 5-HT7 receptor activation on 
neurotrophic factor signalling can be answered by assessing similar intracellular aspects that 
recent transactivation studies have investigated. First, given Vasefi et al. and Samarajeewa et al. 
concluded that long term activation of PDGFβ and TrkB receptors by 5-HT7 receptors were 
predominantly Gαs-dependent respectively [57, 65], intracellular intermediates that are 
downstream of PKA activation should be investigated. Additionally, an experiment is required to 
answer whether if LP 12 induced short-term increases in PDGFβ and TrkB receptor activity are 
mutually exclusive of each other or if one is dependent on the other. For TrkB, since the 
phosphorylation and expression were elevated at 2 h in primary hippocampal neurons, a Trk 
tyrosine kinase inhibitor, K-252a, should be used to block Y816 activity to see if the PDGFβ 
receptor continues to increase in phosphorylation between 2 h and 4 h after LP 12 treatment. 
Conversely, PDGFβ receptor kinase activity should be blocked, via AG-1296, and it should be 
assessed if TrkB receptor phosphorylation still rises at 2 h and 4 h. These experimental 
conditions will clearly deduce if the short-term changes in PDGFβ and TrkB receptor 
phosphorylation are mutually exclusive or whether if blocking the activity of one could change 
the profile of another in the short-term. Given only the PLCγ1 sites on the RTKs were examined 
in this project (and  the phosphorylation states were found to be elevated), it is quite possible that 
the intracellular mechanism for both short-term and long-term 5-HT7 receptor activation involves 
an increase in Ca
2+
 influx [114]. The exact role of calcium influx should be unraveled by pre-
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incubating the same set of experimental conditions with a calcium chelator , such as BAPTA, 
and an ionophore, such as ionomycin, that can increase intracellular Ca
2+
 influx. Last, the role of 
β-arrestins and phosphodiesterases that regulate the de-phosphorylation of GPCRs and RTKs 
should be tested, respectively.      
In the context of transactivation and neuronal survival, it is easier to postulate the 
physiological relevance of transactivation being pertinent to a safety system that delays neuronal 
death in the absence of growth factors, but this explanation is hard to interpret over a longer time 
course (hours to days). The ability of 5-HT7 receptor agonists to concurrently increase the 
activity of PDGFβ and TrkB receptors in a relatively short time frame such as 4 h gives rise to 
the intriguing possibility that 5-HT7 receptors may play a key role in response to acute neuronal 
stress like excitotoxicity. 
5.2 Short-term activation of 5-HT7 receptors is neuroprotective against neuronal 
excitotoxicity 
 The second objective of this project was to decipher if any short-term changes in PDGFβ 
or TrkB receptor systems caused by 5-HT7 receptor agonists would prove to be neuroprotective 
against excitotoxicity. Indeed, the short-term increases in RTK signalling in primary 
hippocampal neurons and differentiated HT-22 cells increased the expression of PLCγ1 binding 
site as well as the activation of Akt, two events that would be pre-requisites for inhibiting the 
expression of NR2B subunits and its downstream pro-death signalling, respectively. Subsequent 
to all the pre-treatment effects of LP 12, 4 h application of LP 12 protected primary hippocampal 
neurons as well as differentiated HT-22 cells against NMDA insults (Figures 9 & 16, 
respectively). Indeed, in primary hippocampal neurons the expression of the extrasynaptic NR2B 
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subunit appears to be reduced over a sustained period of 2 h to 4 h after agonist application 
(Figure 6A) which further strengthens the proposed mode of neuroprotection by Vasefi et al. 
[103]. Beazely et al., demonstrated that PDGFβ receptor expression is mainly extrasynaptic and 
that they co-localize with NR2B subunits, providing a possible explanation as to why PDGF-BB 
application in hippocampal neurons selectively decreases the cell surface expression of NR2B 
subunits and phosphorylates certain tyrosine sites that increase their internalization kinetics [89]. 
The exact mechanism by which PDGFβ receptors inhibit NR2B subunits should be further 
investigated.      
Vasefi et al., did not investigate the role of TrkB receptors, but Samarajeewa et al. 
showed both rapid (transactivation) and short-term increases (2 h) in TrkB receptor expression 
and activity with LP 12 in various models [65]. This project unravelled an intriguing finding that 
5-HT7 agonists can cause short-term and concurrent increases in both PDGFβ receptor and TrkB 
receptor signalling which may incur a synergistic effect against neuronal excitotoxicity. 
However, the neuroprotection data using MTT assays only utilized RTK inhibitors that were 
specific for PDGFβ receptors (Figure 8) but the lack of neuroprotection with 2 and 4 h 
application of LP 12 in the presence of imatinib indicates the neuroprotection is PDGFβ receptor 
specific and counters the theory that both TrkB and PDGFβ receptor signalling are required to 
happen concurrently in order to prevent NMDA excitotoxicity.      
 The mechanisms by which PDGFβ receptors and TrkB receptors prevent neuronal 
excitotoxicity may be mechanistically and temporally distinct. The PDGFβ receptors physically 
interact with extrasynaptic NR2B containing pools of NMDA receptors given they do not 
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colocalize with PSD-95 (synaptic marker) or with synaptic NR2A subunits [89], and that PDGFβ 
receptor activation reduces expression of NR2B subunits as found in this project along with 
several other reports [37, 89, 103]. This key feature of the PDGF system inhibiting extrasynaptic 
NMDA receptor activity mimics the action of the pharmacological agent memantine which only 
blocks the NMDA receptor ion channel during excitotoxicity, while sparing synaptic NMDA 
receptor activity. Indeed, the neuronal and vascular PDGF system is up-regulated rapidly in vivo 
in response to acute ischemia for neuroprotection and injury repair, respectively [86, 116]. In 
contrast, the activation of the neurotrophin system in acute excitotoxicity is believed to be 
dependent on the synaptic activity of NR2A containing NMDA receptors which leads to CREB 
phosphorylation, leading to the delayed transcription and synthesis of BDNF [75] which can then 
act on Trk receptors and also causes transcription of pro-survival genes against both 
extrasynaptic NMDA receptor signalling and downstream cell death [117]. Given the enhanced 
activity of extrasynaptic NMDA receptors during neuronal excitotoxicity, and the short-term 
downregulation of NR2B subunits by PDGFβ receptors, it is very likely that the PDGF system is 
first in line to sustain synaptic activity by preventing NR2B subunit dependent decreases in 
CREB and ERK phosphorlation [89] which subsequently allows for the synthesis of BDNF and 
the long-term trophic effects of TrkB activation and neuronal survival. Given 5-HT7 receptor 
expression is likely elevated during excitotoxicity (Figure 17), and that its activation between 2 
and 24 h upregulates PDGFβ receptor activity as well as TrkB receptor activity, it is plausible to 
suggest that 5-HT7 receptors can play a critical role in response to ischemia and other forms of 
neuronal excitotoxicity (see schematic in Figure 21). 
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Schematic proposing that 5-HT7 receptor activation under excitotoxic conditions activates PLCγ1 on 
PDGFβ receptors that inhibits the activity of extrasynaptic NMDA receptors which is no longer able to 
inhibit synaptic NMDA receptor activity that is required for BDNF-TrkB mediated neuroprotection. 
5.3 5-HT7 receptors agonists for neuronal excitotoxicity 
 The research presented in this project gives direct evidence for targeting the 5-HT7 
receptor system to (ligand-independently) upregulate the activity of PDGFβ and TrkB receptors 
with only short-term agonist application. In cell biology it is no longer a mystery that GPCRs can 
activate (transiently and long-term) RTKs intrinsically without the need of growth factors and in 
neurobiology specifically, these systems are beginning to be well characterized. Several clinical 
attempts to target neurological disorders with growth factors had great premise but limited 
success due to i) the prolonged deleterious effects of direct activation of RTKs and ii) problems 
with effectively delivering large proteinaceous growth factors to the brain. Short-term use of 5-
Figure 21. 5-HT7 receptors: short-term and long-term activation against neuronal excitotoxicity 
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HT7 receptor agonists for the treatment of acute brain injuries, which all inherently involve 
excitotoxicity, may be beneficial given its robust involvement in concurrently upregulating two 
neurotropic systems that govern the brain's natural responses to injury. However, the use of 
agonists like LP 12 or its recently more bioavailable and brain penetrable analogues, LP 211, for 
neuronal excitotoxicity is still an avenue that needs strengthening through more in vitro and in 
vivo investigation (see section 5.4).  In order for the 5-HT7 receptor to become a new therapeutic 
target for neuronal excitotoxicity the following research questions need to be addressed well 
before the pre-clinical stage: 
 How long do the effects of LP 12 last in neuronal cultures and is extrasynaptic 
NMDA receptor expression and activity restored past 24 h? 
 Can the short-term effects of LP 12 on RTKs be replicated with post-NMDA 
treatment instead of pre-treatment? 
 What are the intermediate signalling components of short-term and long-term 5-
HT7 receptor activation of PDGFβ and TrkB receptors?  
5.4 Limitations and future directions 
 This project had numerous methodical limitations which affect the inferences that can be 
made out of the results presented. First, in primary hippocampal neurons the excitotoxicity 
incurred was merely a 10 min NMDA/glycine exposure after which a washout was performed 
and neurons were allowed to undergo demise for 24 h. Neuroprotection against this form of in 
vitro excitotoxicity is not sufficient evidence for pre-clinical investigation of the agonist given 
physiologically the insult is typically more robust. In order to warrant the pre-clinical 
development of LP 12 or analogs, the neuroprotective effects of the agonists need to be assessed 
using higher NMDA concentrations for longer periods of time or even in the presence of 
glutamate instead of NMDA. In addition to increasing the intensity of the excitotoxic insult, it is 
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imperative to assess if the neuroprotection studies done in this project can be replicated using the 
MAP-2 assay as it will indicate neuronal survival specifically. Second, evidence presented that 
5-HT7 receptors upregulate during excitotoxicity was only drawn from experiments done in 
differentiated HT-22 cells that were shown to be susceptible to NMDA excitotoxicity. Given no 
expression of functional NMDA receptors was detected in this cell line, this piece of evidence 
should still be considered unconfirmed until mRNA analysis or further Western blot analysis of 
NR2 subunit transcripts is performed in differentiated HT-22 cells. Last, experiments were not 
performed (in neuronal cultures or cell lines) to conclusively deduce if short-term effects of LP 
12 on RTK activation are indeed Gαs dependent or whether if Gα12 activation also plays a role.  
 In addition to experiments that could not be performed for various reasons, a key 
limitation that needs to be elaborated upon is the differentiated HT-22 cell line used in this 
project. Even though experiments suggest the differentiated cell line possesses functional PDGFβ 
receptors as well as 5-HT7 receptors, the lack of NR2 subunit detection via western blot impedes 
the conclusions that can be made out of this project (thus far). More sensitive tools like real time-
polymerase chain reaction (rt-PCR) need to be employed to sensitively detect any levels of NR2 
subunit mRNAs in the differentiated cell line. Additionally, cell lysis and Western blot protocols 
need to be optimized to detect NR2 subunits where a higher concentration of SDS (up to 0.5%) 
can be used to lyse differentiated cells, and a higher amount of protein can be loaded (40-45 ug) 
to detect any expression. The data presented in this thesis on the cell line being susceptible to 
excitotoxicity is indeed plausible given differentiation of any cell line is never wholesome, i.e., 
not every immortalized cell is able to escape the cell cycle and sustain a post-mitotic fate. The 
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reduction in viability with 1 mM NMDA for 4 h was on average around 35% suggesting only a 
subset of cells may have been undergoing the differentiation necessary to possess functional 
NR2 subunits, which meant not enough protein was extracted from differentiated cells to be 
detected via western blot. Similar observations supporting only a subset of cells undergoing 
differentiation were reported by Zhao et al. who assessed homocysteine toxicity in differentiated 
HT-22 cells [110]. Experiments in the very near future at Beazely lab will undoubtedly reveal 
whether if this cell line can be used as a model to study NMDA excitotoxicity. In addition to the 
lack of NR2 subunits detected in HT-22 cells, data presented here shows no response of these 
cells to a 10 min application of BDNF (Figure 13). This experiment suffered heavily from not 
having a positive control (perhaps the use of SH-SY5Y cells alongside HT-22 cells) and the 
short application time of 10 min with BDNF. In literature, while variable treatment times with 
BDNF are used in cell lines and primary neurons, it is accepted that any changes in ERK or Akt 
activation can be delayed till 30 minutes post treatment [117]. An additional experiment needs to 
be performed with a longer exposure to BDNF to conclusively rule out the cell line possessing 
non-functional TrkB receptors.      
 The ultimate future direction of this research will be to utilize electrophysiology tools to 
measure miniature excitatory postsynaptic currents (mEPSCs) in hippocampal neurons (or 
differentiated HT-22 cells if found to be successfully differentiated) subject to both short and 
long-term treatment with LP 12. This series of experiments will conclusively unravel the time 
course by which 5-HT7 receptors may promote, inhibit or have no effect on NMDA receptor 
activity.      
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5.5 Conclusion 
 The prolonged activation of the 5-HT7 receptor inhibits NMDA receptor function by 
upregulating PDGFβ receptor expression and activity. PDGFβ receptors activation is a biological 
event that occurs in response to neuronal excitotoxicity, but the most toxic form of neuronal 
excitotoxicity occurs in an acute and short-term time frame where prolonged activation with a 
GPCR to upregulate its activity may not be a favourable clinical strategy. This research shows 
evidence of short-term activation of 5-HT7 receptors upregulating both PDGFβ and TrkB 
receptor signalling activity which also proves to be neuroprotective against NMDA 
excitotoxicity, further suggesting that 5-HT7 receptor modulation of NMDA receptors is a novel 
therapeutic target for a multitude of neurodegenerative and neurological pathologies. 
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